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Abstract
This thesis deals with statistical issues in the analysis of complex life history processes
which have characteristics of heterogeneity and dependence. We are motivated, in this the-
sis, by three specific types of processes; i) processes featuring recurrent episodic conditions
ii) multi-type recurrent events, and iii) clustered multi state processes as arise in family
studies.
In chronic diseases featuring recurrent episodic conditions, symptom onset is followed
by a period during which symptoms are present until recovery. In the analysis of data
from such processes, analysis is often based only on the recurrent onset of disease, ignoring
the duration of symptoms. This loss of information may lead to incorrect conclusions
in the analysis of this data. In Chapter 2, we propose a novel model for an alternating
two-state process including symptom-free state and symptomatic state to recognize the
duration of symptoms. This approach reflects the dynamics of individual’s disease process
and helps to understand a course of disease. Intensity-based models with multiplicative
random effects are considered where the disease onset time is governed by a conditionally
Markov intensity and the time of recovery is governed by a conditionally semi-Markov
intensity. A bivariate random effect with one multiplicative component for each intensity
is introduced to accommodate between-individual heterogeneity and a dependence between
bivariate random effect variables offers a natural and more general framework for modeling
the two state process. A copula function is used for the joint distribution of random effects
which retains the marginal features and gives flexible choices of dependence structure.
The proposed model is a semiparametric model for which estimation is carried out using
an expectation-maximization algorithm.
The aforementioned problem leads us to investigate the impact of ignoring symptom
duration in a randomized trial setting. In Chapter 3, we define two risk sets for recurrent
event analyses: one involves including individuals during their symptomatic period, and
the other excluding individuals from the risk set during symptomatic periods. In a clinical
trial, the balance between treatment groups in unmeasured confounders present at the
time of randomization can be lost following randomization as the risk set changes, thus,
retaining individuals in the risk set is a common approach. Here we examine asymptotic
iv
and empirical biases of estimators from the rate-based models when two different risk sets
are applied. We assume that the true underlying process is an alternating two-state process
where the true risk set is the one that excludes individuals when they are experiencing an
exacerbation. We consider two scenarios of the true model. First, there is no between-
variation for each process and no dependence between two processes. The second scenario is
to use the proposed dependent alternating two-states model in Chapter 2. Issues of model
misspecification and causal inference are considered. When focus is on clinical trials, power
implications of risk set misspecification is of interest.
In Chapter 4, attention is directed at multiple recurrent events where each endpoint
is of interest. The use of composite endpoint which is the time point of the first event
of any type is a simple way to analyse such data. However, when multiple events are of
comparable importance, use of a composite endpoint analysis may not be suitable. We
propose a copula-based model for multi-type recurrent events where each type of recurrent
event process arises from a mixed-Poisson model and random effects linking the events
through a copula function. When more than two types of events are considered, composite
likelihood is adopted to ease the computational burden, and simultaneous and two-stage
estimation are explored.
An aim of family studies is typically to gain knowledge about factors governing the
inheritance of diseases. One may be interested in examining a dependence of disease onset
between family members, and in identifying genetic markers associated with heritable dis-
ease. A common procedure is to collect families is through probands in which such affected
individuals are selected from a disease registry and their family members (non-probands)
are, then, recruited for examination. This approach to sampling families motivates us to
consider the disease onset process along with survival since the proband must be diseased
and alive to be recruited, and family members may need to be alive. In Chapter 5, we
propose a model for a clustered illness-death process for family studies which accounts for
the semi-competing risks problem for disease onset as well as biased sampling. We model
within-family association in the age of disease onset via a copula function and applied to the
possibly latent disease onset time and incorporate survival through a marginal illness-death
model. The ascertainment condition is reflected in the likelihood or composite likelihood
construction. Two study designs regarding the recruitment of family members are consid-
v
ered. One involves the collection of disease history from family members via the proband
or medical records. The other requires family members to undergo a medical examination
in which case they must be alive at the time of the family study. Family data alone are
insufficient to estimate all of the parameters of the illness-death processes. We therefore
make use of auxiliary data including the population mortality data and additional registry
data to address the estimatability issue. Another source of auxiliary data is current status
survey. The issue of missing genetic markers is also addressed in each study design.
vi
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Individuals experience events during their lifetimes, and it is important to analyze such data
to understand the processes governing events occurrence. The methods for analysis depend
on the nature of data and how that data are acquired and such issues are particularly
important for the analysis of life history data. In many settings, it is of interest to study
the dynamics of disease processes over the course of an individual’s lifetime, variation in
patterns across individuals, how interventions may affect such processes, and relationships
between more than two processes. From a statistical point of view, estimation of the
probability of disease incidence and event occurrence, covariate effects, and measures of
dependence are often of interest. This thesis is concerned with three different problems: i)
analysis of recurrent episodic conditions reflecting the onset and duration of symptomatic
periods in studies of chronic diseases, ii) multiple recurrent events possibly arising due to
the same underlying cause which are therefore associated, and iii) clustered multi-state
data arising in the conduct of family studies. Dependence modeling and dealing with
heterogeneity are themes in each of these problems. Other themes are the impact of biased
sampling schemes and the use of auxiliary data which arise in the third problem.
This introductory chapter begins with an overview of statistical methods for lifetime
1
data, describes the motivating problems which are used in the thesis, and briefly discuss
the contents of the thesis.
1.2 Brief Overview of Lifetime Data Analysis
Methods for the analysis of lifetime processes have been extensively developed to deal
with problems in medicine, economics, actuarial science, and engineering. Examples of
such processes include in health research the onset and progression of cancer, recurrent
hospitalizations, destruction of joints over time in arthritis, etc. In this thesis, we focus
on recurrent event processes and multistate processes. There are several frameworks for
recurrent event data analysis including intensity-based methods, rate-based models and
random effects models (Lawless and Nadeau, 1995; Cook and Lawless, 2007). We review
these briefly in Section 1.2.1. Multi-state processes are of use for competing risks or the
study of progressive or reversible disease processes. We review related statistical methods
for multi-state processes in Section 1.2.2.
1.2.1 Recurrent Event Data
Recurrent event processes generate events repeatedly over time. Such processes arise in
many fields within health research including the occurrence of asthma attacks in respirology
trials, epileptic seizures in neurology studies, and recurrent hospitalizations in affective
disorders (Cook and Lawless, 2007). Statistical models for recurrent events can be specified
in terms of intensity functions for point processes which offers a useful framework for the
analysis of such data (Andersen and others , 1993).
Let Tik denote the time of the kth event for individual i in a sample of n independent
individuals, i = 1, . . . , n. Let Ni(t) =
∑∞
k=1 I(Tik ≤ t) count the number of events occurring
over [0, t] for individual i where dNi(t) = 1 if an event occurs at time t, and dNi(t) = 0
otherwise. If Xi(t) is a vector of covariates for individual i, {Xi(t), 0 < t} denotes the
covariate process. We let Hi(t) = {Ni(s), Xi(s), 0 ≤ s < t}. If we let Ci denote the right
censoring time, Yi(t) = I(t ≤ Ci) is an at risk indicator for the event. Throughout this
2
thesis we suppose the observation process {Yi(t), 0 ≤ t} is independent of the event process





Let H̄i(t) = {Yi(s), N̄i(s), Xi(s), 0 ≤ s < t} denote the history of the observation, observed
event process, and external covariate process at time t; we assume for simplicity the co-
variate process is external. Then the intensity function is defined as the instantaneous
probability of event occurrence at time t given the process history, and is written as
lim
∆t↓0
P (∆N̄i(t) = 1|H̄i(t))
∆t
= Yi(t)λ(t|Hi(t))
where ∆N̄i(t) = N̄i(t + ∆t
−) − N̄i(t−) is the observed number of events over the interval
[t, t+ ∆t). Here
λ(t|Hi(t)) = lim
∆t↓0
P (∆Ni(t) = 1|Hi(t))
∆t
is the intensity function for the underlying recurrent event process. Full specification of
the intensity function requires one to condition on the history of event process. For the
examination of treatment effects in clinical trials this therefore is not an ideal basis for
analysis (Kalbfleisch and Prentice, 2011).
Under the assumption of modulated Poisson processes, the rate function given fixed
covariates, say, where Hi(t) = {Ni(s), 0 ≤ s < t,Xi} is defined as
λ(t|Hi(t)) = lim
∆t↓0




P (∆Ni(t) = 1|Xi)
∆t
= ρi(t),
and the corresponding mean function is µi(t) = E[Ni(t)|Xi] =
∫ t
0
ρi(s)ds. The most com-
mon framework for modeling covariate effects is multiplicative models of the form
ρi(t) = ρ0(t) exp(x
′
iβ).
The baseline rate function can be parametrized or semiparametric models can be specified.
Andersen and Gill (1982) proposed a semiparametric Cox-type model and provided the
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large sample properties of estimators through martingale theory. The partial likelihood






Yi(u) {xi(u)− x̄(β, u)} dNi(u) (1.1)
where x̄(β, t) = S(1)(β, t)/S(0)(β, t) with S(k)(β, t) = n−1
∑n
i=1 Yi(t)xi(t)
⊗k exp(x′i(t)β), k =
0, 1, 2.
Random Effects Models
To accommodate between-subject variability, we introduce random effects into the Poisson
model to obtain a mixed Poisson model of the form
λ(t|Hi(t), ui) = lim
∆t↓0
P (∆Ni(t) = 1|Hi(t), ui)
∆t
= uiρi(t)
where Ui is an unobservable nonnegative random variable independent of Xi(t) with mean
1 and variance φ. Note that the interpretation of covariates effects are conditional on
random effects ui, which means that the marginal covariate effects are more complicated.
The unconditional intensity function for a mixed Poisson process is of the form
λ(t|Hi(t)) = lim
∆t↓0
P (∆Ni(t) = 1|Hi(t))
∆t
= ρi(t)E[Ui|Hi(t)]
which depends on the precise random effects distribution adopted. A number of distri-
butions for Ui are available with commonly adopted ones including the gamma, inverse
Gaussian, positive stable, and log-normal distributions (Hougaard, 2000).
Robust Marginal Methods
If interest lies in marginal features such as the rate or mean functions in order to as-
sess covariate effects, robust methods are often preferable (Cook and Lawless, 2007). Lin
and others (2000) proposed semiparametric multiplicative models for the mean and rate
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functions for the counting process with fixed covariates xi(t) = xi. This has the form
E[dNi(t)|Yi(t), xi)) = ρ0(t)dt exp(x′iβ).
The estimating equation for β is equivalent to (1.1) under the Poisson assumption. To
provide protection against extra-Poisson variation or other forms of misspecification, robust
variance estimates are required for valid inferences.
1.2.2 Multi-state Processes
A multi-state model is a model for a stochastic process with a discrete states which is often
used to describe life history processes changing over a period of time (Hougaard, 1999). It
is a useful framework describing the progression of retinopathy in diabetes, joint damage in
psoriatic arthritis, or cancer and death in oncology (Cook and Lawless, 2018). Multi-state
processes often enable one to calculate transition probabilities over a period of time, or
marginal state occupancy probabilities. We introduce various multi-state models in this
section. Note that we are primarily concerned with fixed covariates here.
Intensity functions
Let Zi(t) denote the state occupied at time t for an individual i with state space {1, 2, . . . , K}.
and Hi(t) = {Zi(u), 0 ≤ u < t, xi} denote the history of state occupancy over [0, t] where





−) = l|Zi(t−) = k,Hi(t))
∆t
= λkl(t|Hi(t))
for all k 6= l and k, l ∈ {1, . . . , K}. We can construct the likelihood for a specific individual
sample path using intensity functions.
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Markov and Semi-Markov Models
Markov processes are commonly used, for which the transition intensities depend on only
the state currently occupied. In this setting, the time scale is the global time (i.e. the time
since the origin of the process). Then, the transition intensities are of the form
λkl(t|Hi(t)) = Yik(t)λkl(t|xi)
where Yik(t) = I(Zi(t




transition probability matrix P (s, t|xi) can be obtained by product integration as




where Λ(t|xi) is a K ×K matrix with Λkl(t|xi) in the(k, l) entry, j 6= k, −
∑
l 6=k Λkl(t|xi)
in the diagonal entries, and I is an identity matrix of size K (Andersen and others , 1993).
Sometime it is more natural to use the time since the most recent transition as the time
scale. Examples of such settings include studies of the duration for recurrent infections in
chronic bronchitis, studies of the duration of recurrent hospitalizations, and the duration of
depressive episodes among individuals with affective disorder. For semi-Markov processes,
λkl(t|Hi(t)) = Yik(t)hkl(Bik(t)|xi),
where Bik(t) is the time since entry to the current state k.
Heterogeneity and Dependence Modeling
Sometimes individual life history paths exhibit substantial heterogeneity defined by the
presence of considerably more variation than can be accounted for by some base model.
In this case random effects are often useful to accommodate between-subject variation.
This approach is often used in life history as shown in Section 1.2.1 with the conditional
intensity given individual unobservable variables. In a similar fashion with multiplicative
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models, the conditional transition intensities are of the form
λkl(t|Hi(t), uikl) = uiklYik(t)λkl(t|xi)
where Uikl is a latent non-negative random variable introduced to account for variation
between individuals, and uikl is its realized value.
When an individual experiences multiple processes, interest may lie in jointly model-
ing them and measuring the dependence between them. One approach readily adopted
involves random effects where the multiple processes are linked via latent variables. While
quite common, this framework does not provide easily interpretable marginal covariate ef-
fects or measures of association. Copula models offer a natural alternative where marginal
processes are jointly modeled by copula functions (Joe, 1997). This formulation deter-
mines a dependence structure only through the copula while retaining the simplicity of the
marginal models.
A copula function C(v1, . . . , vK) in K dimensions is defined as a multivariate distribution
function with marginal uniform [0, 1] distribution; i.e. V1, . . . , VK are uniform [0, 1] random
variables (Joe, 1997). We can then write
C(v1, . . . , vK) = P (V1 ≤ v1, . . . , VK ≤ vK).
For simplicity of illustration, we consider the progressive K + 1 state process and let Wk
be a the sojourn time in state k, k = 1, . . . , K (He and Lawless, 2003). Let Fk(t|x) be the
survival function of Wk given X = x. Then the joint survival function F(w1, . . . , wK |x) =
P (W1 ≥ w1, . . . ,WK ≥ wK |x) can be specified via a copula as
F(w1, . . . , wK |x) = C(F1(w1|x), . . . ,FK(wK |x)).
As a commonly used measure of dependence for two pairs of random variables (T1j, T1k)
and (T2j, T2k), Kendall’s τ is defined as
τ = P ((T1j − T2j)(T1k − T2k) > 0)− P ((T1j − T2j)(T1k − T2k) < 0),
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and this is often used in copula modeling as the summary dependence measure. One of
the widely used classes of copula function is the Gaussian copula, which has the form
C(v1, . . . , vK) = ΦR(Φ−1(v1), . . . ,Φ−1(vK)),
where ΦR is a joint cumulative distribution function of a multivariate normal distribution
with mean zero and correlation matrix R and Φ(·) is the standard normal distribution
function. The Archimedean copula family is also popular, in which the copula functions
have the form
C(v1, . . . , vK) = ψ−1(ψ(v1;φ) + . . .+ ψ(vK ;φ);φ),
where ψ(·;φ) is a so-called the generator function and φ is a dependence parameter. The
Clayton copula is a member of the Archimedean family (Genest and Rivest, 1993), given
by
C(v1, . . . , vK) = (v
−φ
1 + . . .+ v
−φ
K −K + 1)
−1/φ.
1.3 Studies and Motivating Applications
Here we will briefly describe some motivating problems which will be revisited in this thesis.
1.3.1 Recurrent Hospitalizations in Affective Disorder
The data of a registry of recurrent hospitalizations in Denmark were collected over the
period 1994-1999 to study affective disorder (Kessing and others , 2004). All patients who
entered the study had been diagnosed with having affective disorder and being hospitalized
at least once between 1994 and 1999. This selection condition was applied to a total of
10,523 patients. The number of males is 6,721 (63.9%) and the number of females is 3,802
(36.1%). Over the study window the average number of admissions is 1.62 (SD = 1.72),
with a minimum of 1 and a maximum of 90. The data is collected prospectively following
the start of the first hospitalization.
Figure 1.1 illustrates profiles for a sample of 10 patients. The solid line indicates the
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Figure 1.1: Profiles of patients from the Danish psychiatric hospitalization study
state of being in hospital and the dotted line indicates state of being out of hospital.
From this plot, we observe that some hospitalizations are of an appreciable duration,
which motivates the use of an alternating two-state process. The data were censored
at the time of the end of the study on December 31, 1999, at the time of death, or if
patients were diagnosed with organic disorder, schizophrenia or schizo-affective disorder.
The classification of the type of affective disorder was made at the date of discharge from
the hospital, thus the type of disorder was time-dependent; patients were hospitalized with
a diagnosis of unipolar or a diagnosis of bipolar affective disorder. A total of 9417 patients
had been diagnosed with unipolar disorder and 1106 patients had been diagnosed with
mania or bipolar disorder at the first discharge. The number of total re-admissions is 6498
and the the duration of the subsequent hospitalizations varied from 0 to 1253 days (mean
= 43.9, SD =56.4) (Kessing and others , 2004). We revisit this study in Chapter 2 to
illustrate the fitting of an alternating two-state model we develop in that Chapter.
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1.3.2 A Herpes Simplex Trial
Herpes simplex virus infection causes recurrent outbreaks of symptoms lasting typically
two to four weeks of duration. A multicenter open-label randomized two-period crossover
trial was conducted to compare the efficacy of suppressive therapy versus episodic therapy
(Romanowski and others , 2003). Suppressive therapy was valacyclovir at a dosage of 500
mg once daily and episodic therapy was valacyclovir at a dosage of 500 mg twice daily for 5
days after the outbreaks of symptoms. If herpes outbreaks in the suppressive arm patients
received episodic therapy for 5 days and returned to suppressive therapy after 5 days. A
total of 202 patients completed the study for two 24-week period of study out of a total
of 225 patients at enrollment. After the first period of study patients switched to another
therapy so that each patients received both treatments for the 48-week study period. The
mean of total number of outbreaks for the first period is 4.019 with the standard error
of 3.898. The mean of symptom duration is 24.1 days with a minimum of 1 day and a
maximum of 175 days. The variation of the duration of symptom inspires us to investigate
different approaches to defining the risk sets (i.e. including or excluding individuals when
they are experiencing events). We revisit this study in Chapter 3.
1.3.3 Iron Supplementation in Malnourished Children
Malnutrition in children in low-income countries has been identified as a cause of immune
deficiency and susceptibility to infectious diseases since activation of the immune system
in response to infection requires additional energy. Examples of infectious diseases arising
due to malnutrition are opportunistic pathogens and fungus, noma, respiratory, intestinal
infections, tuberculosis, measles and other chronic infections (Ambrus, 2004; Schaible and
Stefan, 2007). Iron deficiency, which is also prevalent in developing countries, causes anemia
and a deficiency of red blood cells. Lemaire and others (2011) conducted a study to examine
the efficacy of iron-containing micro-nutrient powder (iron MNP) on the risk of infections in
malnourished children. In a randomized clinical trial, 268 Bangladeshi children, aged 12-24
month, and moderately-to-severely malnourished with a hemoglobin concentration between
70 and 110 g/L, were recruited in two phases, 12/2007-06/2008 and 07/2008-01/2009,
respectively. Iron MNP were provided to 136 children daily for 2 months and the remaining
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children were provided placebo powder. The primary endpoint was the occurrence of
infections and associated symptoms such as diarrhea, dysentery, lower respiratory tract
infections (LRTIs), cough and fever. During the 2 months intervention period, the incidence
of infections was assessed every other day, whereas after the intervention period, it was
assessed weekly. Interest may lie in measuring dependence between the onset of multiple
infections, which motivates a joint model for multi-type recurrent events. We revisit this
study in Chapter 4 to illustrate the use of a multi-type recurrent event model.
1.3.4 Psoriatic Arthritis Family Study
PsA(psoriatic arthrists) is an immune-mediated inflammatory disease occurring commonly
in patients with psoriasis. Its symptoms include peripheral joints and spinal pain or
stiffness, enthesis, and dactylitis (Gladman, 1991). The Centre for Prognosis Studies in
Rheumatic Disease at the University of Toronto maintains a Psoriatic Arthritis Clinic,
which was established in 1976 and has been following patients since its formation. Upon
entry to the clinic, patients undergo a detailed examination and provide serum samples.
Follow-up clinical and radiological assessments are scheduled annually and biannually to
track the changes in joint damage and functional ability, and serum samples are taken at
clinic visits to measure the changes of markers (Cook and Lawless, 2014). As of April of
2017, 1436 patients have been recruited to University of Toronto Psoriatic Arthritis Reg-
istry (UTPAR) with the range of the date of birth from 1893 to 1997. A median of age at
the first assessment is 44.1 and the mean of age at PsA is 38.0 (SD = 13.6). A family study
was carried out at this registry to examine familial aggregation in the occurrence of PsA.
Among the 1436 individuals, 150 were selected for family studies as probands. Figure 1.2
gives an example Lexis diagram for a family in the PsA family studies. The proband was
sampled from the UTPAR in 2001 and two parents of the proband were recruited to the
family study in 2007; the father and mother were born in 1929 and 1934, respectively, and
the proband (son) was born in 1955. We revisit this family study data in Chapter 5 where



































Figure 1.2: Lexis diagram for a family with 3 members; one proband and parents
1.4 Contents of the Thesis
In Chapter 2, we develop models for the analysis of alternating two-state processes, mo-
tivated by studies of chronic diseases in which affected individuals experience recurrent
symptomatic periods, each of which may last for an appreciable time. We formulate a
copula-based model to link a subject-specific multiplicative random effect acting on con-
ditionally Markov intensity for the onset of exacerbations, with a random effect acting
on a conditionally semi-Markov intensity for exacerbation durations. An expectation-
maximization algorithm is described for fitting a joint semiparametric model for the onset
and resolution of exacerbations. An application is given to a study of recurrent hospital-
ization in patients with affective disorder (Kessing and others , 2004).
While marginal rate-based analyses have considerable appeal for the analysis of recur-
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rent exacerbation in clinical trials, relatively little work has been carried out on how to
best handle the duration of symptomatic periods. In chapter 3, we derive the asymptotic
bias of the Nelson-Aalen estimator of cumulative mean function as well as regression coeffi-
cients under an Andersen-Gill model as a function of parameters of an underlying two-state
process. We investigate the impact of the mean duration of the exacerbation durations,
heterogeneity, and dependence on the asymptotic and empirical biases of parameter es-
timates. An application to a trial of individuals with herpes simplex virus is given for
illustration (Romanowski and others , 2003).
When several types of recurrent events may arise, interest often lies in marginal mod-
eling and studying the nature of the dependence structure. In Chapter 4, we propose mul-
tivariate mixed-Poisson model with the dependence between event type-specific random
effects accommodated through a Gaussian copula. Such models retain the simple inter-
pretation of marginal features, separately reflect the heterogeneity in risk for each type
of event, and provide insight into the dependence between the different types of events.
Inference is proposed based on composite likelihood to avoid high dimensional integration.
The relative efficiency of estimators obtained from simultaneous and two-stage estimation
is examined. An application to a study of nutritional supplements in malnourished chil-
dren is given in which the goal is to evaluate the reduction in the rate of several types of
infection (Lemaire and others , 2011).
Chapter 5 considers family studies where accommodating within-family association in
the age of disease onset is critical when studying the genetic basis of chronic disease. In
family studies families are typically recruited by the identification of an affected individual
from a disease registry, called the proband, whose disease onset time is right-truncated. The
disease status, and possibly onset times of other family members, called non-probands, is
then collected; sometimes this is retrospectively reported and sometimes non-probands are
required to undergo examination to determine their disease status. Relatively little work
has been done on the effect of mortality on inferences about the dependence of disease
processes. We construct likelihoods for family data based on a marginal illness-death
model where the joint distribution of the age at disease onset is considered under complex
sampling schemes. When the disease is rare and data are insufficient, auxiliary data can be
used to augment the likelihood and facilitate estimation. We apply the proposed methods
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to the analysis of a family study of psoriatic arthritis carried out at the University of
Toronto (Pollock and others , 2015; Zhong and Cook, 2016).





Modeling for Alternating Two-state
Processes Via Copulas
2.1 Introduction
Many chronic diseases are characterized by recurrent periods of time during which symp-
toms are manifest. Examples include recurrent exacerbations in individuals with respira-
tory disease (Grossman and others , 1998), recurrent bouts of depression among individuals
with affective disorder (Garber and others , 1988), or recurrent hospitalization in patients
with cardiovascular disease (Borer and others , 2012). In such settings, maximum like-
lihood estimation requires joint modeling of both the onset and duration of recurrent
symptomatic periods. For convenience we use the term “exacerbation” to represent the
condition in which the disease is in an “active” state to represent infections, flares of
symptoms, hospitalizations, etc.
Intensity functions play a central role in the analysis of data from multistate processes
(Andersen and others , 1993) and intensity-based models can provide useful insight into fac-
tors governing event occurrence (Aalen and others , 2008). For processes featuring recurrent
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alternating sojourns in states, however, several aspects must be addressed including the
time scale of the intensity functions. For conditions such as chronic bronchitis or chronic
obstructive pulmonary disease, there is a gradual increase in lung damage due to repeated
exacerbations which increase the risk of symptom outbreaks over time. Likewise, for pa-
tients with cardiovascular disease, as the condition deteriorates individuals are at increased
risk of hospitalization. We therefore consider a model in which the risk of symptom onset
for each individual can be characterized by a modulated Markov intensity function to allow
the risk to change as the time with the disease condition increases. When symptomatic
periods arise, they often follow a natural course, as is the case with episodic infections
leading to symptom exacerbation in respiratory disease. Moreover, upon the onset of an
exacerbation standard interventions may be delivered to ameliorate symptoms and resolve
the symptomatic period. In both cases the resolution process begins upon the onset of
the symptomatic period motivating the use of a modulated semi-Markov model for the
duration of symptomatic periods.
A second complication is that there can be considerable unexplained heterogeneity
between individuals in the propensity for, and duration of, symptomatic periods. Moreover,
individuals at higher risk of exacerbations may also tend to have shorter sojourn times in
the exacerbation state; in studies of infectious disease this can arise if some individuals
live in an area putting them at high risk of reinfection, for example. To accommodate
this type of heterogeneity we introduce a bivariate random effect in which one component
acts multiplicatively on the Markov intensity for the onset of symptoms and the other acts
multiplicatively on the semi-Markov intensity for symptom duration.
The primary purpose of this Chapter is to present a model for an alternating two-state
process which has a suitable time scale for the two intensities, accommodates heterogene-
ity in the propensity for and duration of symptomatic periods, and allows for correlated
random effects for the two conditional intensities. The remainder of this chapter is orga-
nized as follows. In Section 2.2 the formulation of the model is given in detail including
the copula model used to accommodate dependence in the random effects. The marginal
likelihood is derived and an expectation-maximization algorithm (Dempster and others ,
1977) is given to facilitate semi-parametric analysis; variance estimation is also given with
details provided in the Appendix 2.A. Simulation studies are described and reported on
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in Section 2.3 where we study the impact of misspecifying the random effect distribution.
In Section 2.4 we fit the model to data from a Danish study on repeated hospitalizations
in individuals with affective disorder (Kessing and others , 2004). Concluding remarks are
given in Section 2.5.
2.2 Modeling Heterogeneous Hybrid Markov/Semi-
Markov Processes via Copulas
Figure 2.1: A two-state diagram for chronic diseases with recurrent symptomatic episodes
Consider the two-state diagram in Figure 2.1. We suppose each individual i in a sample
of m independent individuals starts their process at time t = 0, which corresponds to
the time of disease onset i = 1, . . . ,m. Let Sik be the onset (start) time for the kth
exacerbation, Tik denote the resolution time of the kth exacerbation, andWik = Tik−Sik the
duration of kth exacerbation. The counting process {Nij(u), 0 < u} records the cumulative
number of j → 3− j transitions experienced by individual i over (0, t], for j = 1, 2, where
Ni1(t) =
∑∞
k=1 I(Sik ≤ t) and Ni2(t) =
∑∞
k=1 I(Tik ≤ t). Let Zi(s) = 1 if individual i is
symptom-free at s > 0, Zi(s) = 2 if they are symptomatic, and Yij(s) = I(Zi(s
−) = j),
j = 1, 2. Moreover, we let Xi1(t) and Xi2(t) be column vectors of external time-dependent





′. The history of
the process is denoted Hi(t) = {(Ni1(s), Ni2(s)), Xi(s), 0 < s < t}. The complete intensity
function for j → 3− j transitions for individual i is
lim
∆t↓0




where ∆Nij(t) = Nij(t+ ∆t
−)−Nij(t−), j = 1, 2, i = 1, 2, . . . ,m.
If interest lies in events occurring over the period (0, A], where A is a common ad-
ministrative censoring time, let C†i denote a random censoring time assumed to be inde-
pendent of the multistate process. We then let, Ci = min(A,C
†
i ), denote the net censor-




for j = 1, 2, N̄i(t) = (N̄i1(t), N̄i2(t)), and {N̄i(s), 0 < s} denote the observed bivariate
counting process. We assume that censoring can occur at any state. We, here, define
Wi,Ni2(Ci)+1 = Ci − SiNi1(Ci) as a censoring time if censoring occurs during exacerbation;
otherwise Wi,Ni2(Ci)+1 = 0. The complete history of the observation and event processes
is then H̄i(t) = {N̄i(s), Yi(s), Xi(s), 0 ≤ s < t}. We assume that two transitions cannot
occur at the same time.
Let Ui = (Ui1, Ui2)
′ denote a bivariate individual specific random effect and consider a
conditional intensity given Ui = ui as
lim
∆t↓0
P (∆N̄ij(t) = 1|H̄i(t), ui)
∆t
= λ̄ij(t)|H̄i(t), ui).
Under independent censoring (Kalbfleisch and Prentice, 2011) we can write
λ̄ij(t)|H̄i(t), ui) = Ȳij(t)λij(t|Hi(t), ui).
The role of the random effect here is to accommodate heterogeneity in the risk and the
duration of events and to account for the dependence between the two processes.
Multiplicative semiparametric models can be expressed as follows. For the conditionally
Markov intensity for 1→ 2 transition corresponding to the onset of symptoms, we let
λi1(t|Hi(t), ui1) = ui1Yi1(t)dΛ01(t) exp(x′i1(t)β1).
For the conditionally semi-Markov intensity for 2 → 1 transitions representing resolution
of symptoms, we let
λi2(t|Hi(t), ui2) = ui2Yi2(t)dΛ02(Bi(t)) exp(x′i2(t)β2)
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with Bi(t) = t − SNi1(t−) represents the time since symptom onset. Note that the terms
Λ0j(·) are infinite dimensional functions, but we informally write θj = (Λ0j(·), β′j)′, for




A bivariate random effects distribution can be formed through the use of a copula
function C(v1, v2), a bivariate distribution function with uniform [0, 1] margins (Joe, 1997).
The copula enables us to link any pair of marginal random effect distributions to obtain a
bivariate distribution. The Gaussian copula is widely used and has the form C(v1, v2; ρ) =
Φρ(Φ
−1(v1),Φ
−1(v2)) where Φρ(·) is a joint cumulative distribution function of a bivariate
normal random variable with mean (0,0)’, variances of one, and correlation coefficient ρ.
The Archimedean family of copulas (Genest and Rivest, 1993) include the Clayton copula




2 − 1)−1/ρ which is widely used in survival analysis. If we let
Gj(uj;σj) denote the marginal c.d.f for Uj for j = 1, 2, then
P (U1 < u1, U2 < u2;φ) = G(u;φ) = C(G1(u1;φ1), G2(u2;φ2); ρ) (2.2.2)
denote the bivariate c.d.f indexed by φ = (φ1, φ2, ρ)
′ (Nelsen, 2006); we then let ψ = (θ′, φ′)′.







where gj(uj) is the marginal p.d.f for Uj for j = 1, 2. We consider both the Gaussian
copula and the Clayton copula for which Kendall’s τ is given by 2arcsin(ρ)/π and ρ/(2+ρ),
respectively. If there is a strong positive correlation between the two transitions, individuals
at increased risk of 1 → 2 transition are at increased risk in 2 → 1 transitions (e.g. the
resolution of exacerbation) which results in frequent short exacerbations. This pattern
is often seen empirically. The severity of the chronic condition can be measured by the
number of occurrence of excerbations; but this must be examined in concert with the
sojourn time distribution.
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then P (Zi(s), 0 < s < Ci|ui, xi(s), 0 < s < Ci; θ) = L12i1L21i1 , i = 1, . . . ,m.
Since dG(ui;φ) cannot be factored, direct maximization of (2.2.3) is challenging. We
adopt an expectation-maximization algorithm (Dempster and others , 1977) to facilitate
semiparametric analyses.
Given the random effects we decompose the complete data log-likelihood into two parts
as










To implement the EM algorithm, we treat the random effects as missing data and the data
on the event process as observed. Let ψ(k) = (θ′(k), φ′(k))′ denote the estimate of ψ at the
kth iteration. In the E-step, we take the expectation of the complete log-likelihood (2.2.4)
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whereQ(ψ;ψ(k)) = E[lC(ψ)|Hi(Ci);ψ(k)], Q1(θ;ψ(k)) = E[l1(θ)|Hi(Ci);ψ(k)], andQ2(φ;ψ(k)) =














P (Hi(Ci)|ui, xi(s), 0 < s < Ci; θ(k))dG(ui;φ(k))
(2.2.6)
where we write P (Hi(Ci)|ui, xi(s), 0 < s < Ci; θ) for P (Zi(s), 0 < s < Ci|ui, xi(s), 0 < s <
Ci; θ) for convenience. The integrals in the numerator and denominator of (2.2.6) do not
have closed forms so we use numerical integration by Gaussian-Quadrature with 32 nodes
for each dimension. Here we exploited OpenMP in C++ to make use of open multi-processing.
We let ν
(k)
ij = logE[Uij|Hi(Ci);ψ(k)] at the kth iteration. At the (k + 1)th M-step, we
solve equations Uβ1(β1;ψ
(k)) = 0 and Uβ2(β2;ψ






























































I(wh` ≥ wij)x⊗rh2 (sh` + wij) exp(x
′
h2(sh` + wij)β2 + ν
(k)
h2 ),
for r = 0, 1.
Given β̂
(k+1)
j , j = 1, 2, the estimates of the cumulative baseline intensities have the


































for the onset and duration of exacerbations respectively. The maximization of (2.2.5) in
the semi-parametric setting can be easily carried out since Q1(θ;ψ
(k)) can be maximized
using the coxreg function in R with ν
(k)
ij treated as an offset term. The estimate φ̂
(k+1) is




using a general optimization software such as the optim function in R. The E-step and
M-step are repeated iteratively until the following stopping rule is satisfied:
max(|ψ(k+1) − ψ(k)|) ≤ ε
where ε = 10−4 is used here.
To estimate standard errors, we use Louis’s formula since the EM algorithm does not
provide the observed information matrix directly (Louis, 1982). The observed information
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where ψ̂ is the estimate of ψ. The score functions and the partial derivatives of score
functions are provided in Appendix 2.A. The asymptotic distribution of estimators arising
from a semiparametric model with Gamma frailty was investigated by Parner and others
(1998) but the asymptotic distribution for bivariate frailty model requires development. We
will show subsequently that the empirical performance is very good. Since the dimension of
I(ψ̂) increases as the number of individuals in the dataset increases, a convenient alternative
is to use a model with piecewise constant baseline intensities.
2.3 Simulation Studies
Simulation studies were conducted to evaluate the finite sample performance of the es-
timators and the validity of the variance estimates from the joint analysis of Section 2.2
using the Gaussian copula, and the Clayton copula. We also examined the impact of model
misspecification through the use of an independence model. The independence model is
obtained by setting Ui1 ⊥ Ui2; the model becomes the two independent frailty models.
We let A = 2 denote an administrative censoring time for individual i and generate data
over the interval (0,2], We adopt an independent random censoring Ci which follows an
exponential distribution with rate − log(0.9)/2 giving 10% censoring i.e. P (Ci < 2) = 0.1.
We consider the case of a fixed covariate and let xi be the indicator of a randomized treat-
ment where xi = 1 if they are assigned to receive experimental treatment and xi = 0
otherwise.
Under a time-homogeneous model, the intensity for the onset of exacerbations is λi1(t|Hi(t), ui) =
ui1λ01 exp(xiβ1) and the resolution of exacerbations is governed by a hazard function
λi2(t|Hi(t), ui) = ui2λ02 exp(xiβ2). We set λ01 = 2, λ02 = 10, β1 = log(0.75), and
β2 = log(1.25). We let Uij have log-normal or gamma distributions with E(Uij) = 1
and Var(Uij) = φj = 0.4 for j = 1, 2, and we link ui1 and ui2 with the Gaussian copula or
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the Clayton copula. Settings considered include with Kendall’s τ = (−0.25, 0, 0.25) for the
Gaussian copula and Kendall’s τ = (0.25, 0.5) for the Clayton copula. We generate 1000
replicates in each scenario with sample sizes of m = 500 individuals.
Table 2.1, 2.2, and 2.3 reports results from the joint copula model and the misspecified
independent frailty model with Ui1 ⊥ Ui2. The empirical biases from the joint model are
small, the empirical and average estimated standard errors of the parameters are in good
agreement, and the empirical coverage probabilities are close to the nominal 95% level
for all scenarios. From the independent frailty model, we observe that small biases in β1
and β2 and the empirical coverage probabilities are close to the nominal level. However,
the frailty variance of resolution of exacerbation, φ2, has non-negligible bias and the lower
empirical coverage probabilities than the nominal 95% level, particularly when Kendall’s
τ is negative with the Gaussian copula and a strong positive dependence is present with
the Clayton copula.
We also conducted additional simulation studies to assess the sensitivity of the analysis
to misspecification of a copula function. The data were generated based on i) the Gaussian
copula and ii) the Clayton copula with the gamma marginal distributions E(Uij) = 1
and Var(Uij) = φj = 0.4 and the remaining parameters were unchanged. We use the
Clayton copula for i), and the Gaussian copula for ii), respectively. Table 2.4 shows the
results under this model misspecification. We note that the estimates of β1, β2 show little
biases whereas φ2 and Kendall’s τ have biases. Therefore, if interest lies in the treatment
effect on the onset of exacerbation or the resolution of exacerbation based on this limited
study, the model provides a modest degree of robustness to misspecification of the copula
function. The variance parameters and the dependence parameters for the two random
effects, however, appear sensitive to misspecification of the copula function. This is in line
with finding of others (McCulloch and Neuhaus, 2011). Note that one could also examine
the empirical bias in estimate of the cumulative baseline Markov transition intensity for
the onset of exacerbations as well as the cumulative hazard for the sojourn times in the
exacerbation state. We do not do this here.
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Table 2.1: Finite sample performance of estimators from semiparametric analyses
of Markov/semi-Markov model under the Gaussian copula with log-normal margins
and a (misspecified) independence model
Gaussian Copula - LN Margin Independence - LN Margin
τ PARAM† BIAS ESE ASE ECP BIAS ESE ASE ECP
-0.25 β1 -0.002 0.080 0.078 0.947 0.003 0.080 0.078 0.941
β2 0.001 0.082 0.085 0.956 -0.013 0.084 0.084 0.939
φ1 -0.001 0.071 0.070 0.947 -0.018 0.068 0.068 0.925
φ2 -0.013 0.101 0.098 0.921 -0.053 0.088 0.089 0.862
τ -0.005 0.083 0.080 0.949
0.00 β1 -0.003 0.076 0.078 0.948 -0.002 0.078 0.078 0.951
β2 -0.001 0.084 0.085 0.944 -0.002 0.087 0.085 0.943
φ1 -0.003 0.070 0.068 0.931 0.000 0.069 0.068 0.947
φ2 -0.012 0.091 0.094 0.935 -0.011 0.090 0.093 0.940
τ 0.003 0.081 0.079 0.945
0.25 β1 0.000 0.076 0.077 0.960 -0.002 0.076 0.078 0.950
β2 0.001 0.082 0.084 0.954 0.015 0.088 0.085 0.939
φ1 -0.002 0.068 0.067 0.940 0.007 0.069 0.067 0.938
φ2 -0.005 0.088 0.090 0.948 0.027 0.096 0.095 0.970
τ 0.011 0.083 0.081 0.945
† True values are β1 = −0.2877, β2 = 0.2231, φ1 = 0.4, φ2 = 0.4.
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Table 2.2: Finite sample performance of estimators from semiparametric analyses of
Markov/semi-Markov model under the Gaussian copula with gamma margins and a (mis-
specified) independence model
Gaussian Copula - Gamma Margin Independence - Gamma Margin
τ PARAM† BIAS ESE ASE ECP BIAS ESE ASE ECP
-0.25 β1 -0.001 0.080 0.080 0.954 0.004 0.080 0.080 0.954
β2 0.000 0.091 0.094 0.962 -0.015 0.089 0.092 0.960
φ1 -0.004 0.054 0.054 0.944 -0.021 0.053 0.053 0.915
φ2 -0.010 0.065 0.065 0.944 -0.034 0.063 0.064 0.896
τ -0.001 0.080 0.078 0.946
0.00 β1 -0.001 0.079 0.080 0.954 -0.001 0.079 0.080 0.954
β2 0.002 0.090 0.092 0.956 0.002 0.091 0.092 0.954
φ1 -0.004 0.051 0.052 0.948 -0.004 0.051 0.052 0.947
φ2 -0.012 0.064 0.064 0.933 -0.012 0.064 0.064 0.935
τ 0.005 0.077 0.079 0.948
0.25 β1 0.000 0.079 0.079 0.950 -0.004 0.079 0.080 0.951
β2 0.000 0.087 0.090 0.961 0.015 0.088 0.091 0.955
φ1 -0.004 0.052 0.051 0.945 0.003 0.052 0.052 0.950
φ2 -0.007 0.066 0.064 0.949 -0.001 0.065 0.063 0.947
τ 0.011 0.079 0.080 0.956
† True values are β1 = −0.2877, β2 = 0.2231, φ1 = 0.4, φ2 = 0.4.
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Table 2.3: Finite sample performance of estimators from semiparametric analyses of
Markov/semi-Markov model under the Clayton copula with gamma margins and a (mis-
specified) independence model
Clayton Copula - Gamma Margin Independence - Gamma Margin
τ PARAM† BIAS ESE ASE ECP BIAS ESE ASE ECP
0.25 β1 0.002 0.079 0.079 0.953 -0.001 0.080 0.079 0.952
β2 -0.001 0.086 0.087 0.956 0.010 0.087 0.088 0.953
φ1 -0.003 0.050 0.051 0.950 -0.003 0.050 0.051 0.948
φ2 -0.013 0.066 0.067 0.932 -0.054 0.059 0.060 0.813
τ 0.001 0.091 0.094 0.949
0.50 β1 -0.001 0.079 0.078 0.958 -0.006 0.079 0.079 0.954
β2 0.003 0.083 0.083 0.943 0.022 0.084 0.085 0.936
φ1 -0.001 0.053 0.051 0.940 -0.003 0.053 0.051 0.939
φ2 -0.011 0.066 0.068 0.933 -0.076 0.056 0.058 0.695
τ 0.007 0.107 0.096 0.944
† True values are β1 = −0.2877, β2 = 0.2231, φ1 = 0.4, φ2 = 0.4.
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Table 2.4: Empirical results of semiparametric modeling under a misspecified copula model
where data are generated by i) the Gaussian copula and ii) the Clayton copula. For i) the
Clayton copula is used and for ii) the Gaussian copula is used for analysis; Kendall’s τ =
0.25
Analysis i) Clayton Copula - Gamma Margin ii) Gaussian Copula - Gamma Margin
PARAM† BIAS ESE ASE ECP BIAS ESE ASE ECP
β1 0.000 0.079 0.079 0.949 0.001 0.079 0.079 0.952
β2 0.001 0.087 0.090 0.961 -0.001 0.086 0.087 0.957
φ1 0.003 0.053 0.052 0.949 -0.008 0.050 0.051 0.942
φ2 0.050 0.074 0.073 0.925 -0.059 0.060 0.060 0.804
τ 0.049 0.096 0.095 0.919 -0.053 0.078 0.081 0.904
† True values are β1 = −0.2877, β2 = 0.2231, φ1 = 0.4, φ2 = 0.4, τ = 0.25.
2.4 Recurrent Hospitalization Among Individuals with
Affective Disorder
To investigate the course of depressive or bipolar disorder, the Danish Psychiatric Central
Research Register collected patients experiencing hospitalization with affective disorder
over the period 1994-1999 (Kessing and others , 2004). A total of 10523 patients were re-
cruited and individual data were recorded from the start of the first hospitalization. Kessing
and others (2004) and Cook and Lawless (2013) analyzed this data set by stratification
on the number of prior admissions or by incorporating it as covariate, and concluded an
increased risk of admission with increasing numbers of prior hospitalizations. However, this
does not fully explain the nature of hospitalization process since the duration of the hospi-
talization was not considered. We applied our proposed model to data from a psychiatric
hospital re-admission studies to address this here.










































































EIGHTH AND HIGHER ADMISSION
Figure 2.2: A crude summary of the distributions of the numbers of hospitalizations for
individuals (left panel) and Kaplan–Meier estimates of the survivor functions for the du-
ration of hospitalization stratified by the number of admissions (right panel) in the Danish
Psychiatric Registry
individuals (panel a) and naive Kaplan–Meier estimates stratified by the number of prior
admissions (panel b). The number of prior admissions were categorized into 1, 2, 3, 4, 5, 6,
7, and 8 or more prior admissions. The majority of patients experienced one or two admis-
sions. The right panel in Figure 2.2 shows Kaplan-Meier estimates of the survivor functions
Sj(t) = P (Wij ≥ w) for j = 1, . . . , 7 and S8(t) = P (Wik ≥ w) for k ≥ 8, which indicates
that the duration of hospitalizations tends to be shorter as the number of hospitalization
increases. However, this crude summary of the data is misleading because it does not
account for heterogeneity in the risk of admission or the duration of hospitalizations. As a
consequence the Kaplan-Meier estimates are biased. While inverse probability of censoring
weights can be used to correct for dependent gap times in the recurrent event setting (Lin
and others , 1999; Cook and Lawless, 2007, Sec. 4.4.1), with alternating processes this is
considerably more challenging and modeling the process offers a more convenient approach
for dealing with this.
We consider the data from the admission of the first hospitalization. Gender, age at
first diagnosis, type of disorder at the first discharge and cumulative number of admissions
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Table 2.5: Analysis of hospital re-admission data among individuals with affective disorder
under a Gaussian copula with gamma margins
Admission Discharge
Covariate EST SE p EST SE p
Sex : Female vs. Male 0.186 0.033 < 0.001 -0.184 0.021 < 0.001
Age at first hospitalization (Ref: [0, 20))
[20, 40) -0.202 0.099 0.041 -0.065 0.066 0.325
[40, 60) -0.382 0.098 < 0.001 -0.037 0.066 0.575
[60, 80) -0.433 0.099 < 0.001 -0.095 0.066 0.150
[80,∞) -0.372 0.109 < 0.001 -0.141 0.072 0.050
Type of disorder (Ref: depression)
Bipolar 0.299 0.043 < 0.001 -0.024 0.029 0.408
Cumulative number of admissions (Ref: 1)
2 0.625 0.046 < 0.001 0.095 0.024 < 0.001
3 1.047 0.064 < 0.001 0.243 0.035 < 0.001
4 1.506 0.079 < 0.001 0.309 0.049 < 0.001
5 1.682 0.096 < 0.001 0.580 0.064 < 0.001
6 1.872 0.116 < 0.001 0.705 0.081 < 0.001
7 2.220 0.140 < 0.001 1.042 0.107 < 0.001
≥ 8 3.101 0.090 < 0.001 1.572 0.071 < 0.001
Frailty Variance 0.861 0.055 0.200 0.013
Kendall’s τ -0.367 0.018 < 0.001
were included as covariates. Age at first hospitalization was categorized as age < 20, 20−
40, 40−60, 60−80 and 80 or over. The median of age at first hospitalization is 52 with range
from 10 to 110. The objective of this analysis is to properly address the patients’ cycle of
hospitalization using an alternating two-state models and to identify the risk factors for
the re-admission to a psychiatric hospital and the discharge.
The results of fitting the proposed model are reported in Table 2.5. We found that age
at first discharge had a significant negative effect on the risk of re-admission, however, no
significant effect on the rate of discharge from the hospital; older pateints have a lower rate
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of re-admission and stayed longer in hospital. Patients with a diagnosis of bipolar disorder
are at higher risk for re-admission (RR=1.35; 95% CI: 0.216, 0.38; p < 0.001) and at lower
risk for discharge from the hospital (RR=0.98; 95% CI: −0.08, 0.03; p = 0.408). This result
is consistent with the findings of Cook and Lawless (2013). Sex had a significant impact on
patients’ cycle; men had a higher rate of re-admission (RR= 1.20; 95% CI: 0.12, 0.25; p <
0.001) and a shorter duration of hospitalization (RR= 0.83, 95% CI: −0.23,−0.14; p <
0.001). Here we see a significant increasing trend in the risk of admission and discharge
with increasing number of prior admissions. There are great subject-to-subject variations
in the re-admission rate and the discharge rate among patients (φ̂1 = 0.861, φ̂2 = 0.20).
The estimated Kendall’s τ is −0.367, which means the transition times between the two
states are negatively correlated. Therefore if an individual tends to have a higher rate of
admission to hospital, the one has a lower rate of discharge from hospital leading to the
longer duration of hospitalization.






























CUMULATIVE BASELINE RATE FUNCTION
CUMULATIVE MEAN FUNCTION (X=0)
(a) Admission to hospital
































CUMULATIVE BASELINE RATE FUNCTION
(b) Discharge from hospital
Figure 2.3: Cumulative baseline rate function and cumulative mean function
The solid line in Figure 2.3 displays the estimated baseline cumulative hazard function
of the time to re-admission and time to discharge for males with a depressive disorder aged
[0-20). For the admission to hospital the two functions increases rapidly following the start
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of the first hospitalization reflecting the risk of rapid re-admission. The mean function
increases at a slower rate since individuals included in the risk set may still be admitted
and hence not truly at risk of admission. Beyond this initial period the curves depart at
a much slower rate in part due to the relatively short typical durations of admissions in
relation to the total period of observation. Interest often lies in the marginal mean function











ui1P (Yi1(s) = 1|ui, xi(s))dΛ01(s) exp(x′i1(s)β1)dG(ui)
Since the estimation is based on the semi-parametric model, P (Yi1(s) = 1|ui, xi(s)) is
difficult to calculate; we obtain it via a simulation as follows. First, we generate a data set
of 10,000 individuals based on the estimates obtained for each process upto the follow-up
time. Due to the initial condition, the data were generated from the start of the first
hospitalization. Next, we count the individuals who are in the symptom-free state and
divide it by the total number of individuals at each time point. The dotted line in Figure
2.3 shows the estimated mean function for males with a depressive disorder aged [0-20).
Clearly, it is less than the cumulative hazard function in which the mean function accounts
for the risk set for the onset of re-admission.
Figure 2.4 contains plots of the baseline distributions for the durations of successive
hospitalizations based on the fitted models. These are obtained by estimating the baseline
hazard for the first 7 and then the 8th and subsequent hospitalizations and using these
estimates to compute the corresponding semiparametric estimates of the survival functions.
Compared to the right panel of Figure 2.3, the evidence of a trend is much lower from the
fitted model, in part because the modeled and unexplained sources of heterogeneity have
been accounted for.
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EIGHTH AND HIGHER ADMISSION
Figure 2.4: Survivor functions for the durations of successive hospitalizations based on the
proposed model
2.5 Discussion
We have described a flexible bivariate random effect for the analysis of alternating two-state
processes. This model is appealing when a long duration of episodes is observed and there
is an association between the onset and the resolution of episodes. In particular, patients
may receive treatments while experiencing episodes, which can affect subsequent relapses.
In this setting, the accommodation of duration is sensible in recurrent data analysis. Also
this model is more attractive since we can implement global hypothesis tests for treatment
effects across two processes.
We viewed the recurrent episodes as an alternating two-state processes and formulated
the intensity-based model in Section 2.2 using bivariate mixed models. The time since
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onset of a chronic disease was used as the time-scale for the intensity governing the onset
of exacerbations and a semi-Markov time scale was used for the intensity governing the
resolution of exacerbations. The dependency between two processes is captured by intro-
ducing a copula function for random effects. The EM algorithm was conducted to obtain
maximum likelihood estimators under the semi-parametric setting. The optimization of
parameters for the variance of random effects and Kendall’s τ is computationally intensive
since the evaluation of (2.2.9) is required at every iteration during optimization.
Random effect models have a useful role when modeling multistate processes involving
recurrent sojourns in one or more states when intensity-based analyses are not of interest
(Putter and van Houwelingen, 2015). In the illustrative application insights are gained
into the extent of heterogeneity and the nature of the dependencies. In settings where
mortality rates are appreciable, such as in individuals with advanced chronic obstructive
pulmonary disease, it may be of interest to generalize this model to incorporate a third state
representing death; this would lead to a reversible illness-death model (Cook and Lawless,
2018). When estimating the cumulative mean function in this context, the terminal effect
of death will naturally be accommodated. For the current model a difficulty arose in the
estimation of P (Yi1(t) = 1|ui, xi(t)) so we used resampling techniques to address this. This
could be adopted in the context of a reversible illness-death model as well, but alternative
approaches could also be investigated.
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Appendix 2.A: The Score Functions and the Partial
Derivatives of Score Functions


















































For simplicity, consider the case of a time-independent covariate vector.


















































ui2I(wij ≥ wk) exp(x′i2β2),
where tk is the kth time of transition from 1→ 2 and wk is the kth gap time of transition
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from 2→ 1.





























































The form of l2(φ) depends on the marginal distribution of Ui, and the copula function.
Note that for Gaussian copula with gamma margins or the Clayton copula with gamma
margins, the score functions and the second derivatives of l2(φ) with respect to φ do not
have closed forms and numerical derivatives were obtained using the grad and hessian
functions in R.
The conditional score vector and the components of the conditional information matrix
for the Gaussian copula function with log-normal margins are present here. For conve-
nience, we denote σj = Var(log(Uij) =
√
log(φj + 1) and compute the conditional score
vector and the conditional information matrix with respect to σj and obtain variance of
φj using the delta method.
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+ log(ui1) + log(ui2)
}




















of Recurrent Episodic Conditions
3.1 Introduction
In many chronic diseases individuals are at risk of recurrent episodic flares of symptoms.
Statistical methods for recurrent event analyses have seen widespread application in such
settings, including methods based on the semiparametric Andersen-Gill model (Andersen
and others , 1993), marginal methods based on rate or mean functions (Lawless and Nadeau,
1995; Lin and others , 2000), and frailty models (Lawless, 1987; Klein, 1992; Wienke, 2010).
These methods are geared towards the analysis of recurrent events which are instantaneous,
but in many applications the events signal the onset of a symptomatic period (Hu and oth-
ers , 2011) during which individuals are not at risk of an event. Examples include recurrent
exacerbations of symptoms in individuals with chronic bronchitis (Grossman and others ,
1998), recurrent bouts of depressive episodes in affective disorder (Kessing and others ,
1999), and recurrent outbreaks of symptoms among individuals with herpes simplex virus
infection (Romanowski and others , 2003). There are three approaches to how to han-
dle these risk-free periods in the analyses of data from clinical trials. One may i) retain
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individuals in the risk set for events, as is done in many medical studies, ii) simply re-
move individuals from the risk set while they are experiencing an episode, or iii) model
the onset and duration times based on a two-state model. Alternating renewal processes
were considered by Cox (1967) where the two types of sojourn times are assumed statis-
tically independent. Several random effects (frailty) models have been developed to relax
these independence conditions (Ng and Cook, 1997; Xue and Brookmeyer, 1996; Lee and
Cook, 2018). Intensity-based two-state models offer a powerful framework for studying
and describing the process dynamics, but since they require conditioning on the the pro-
cess history they do not admit estimates of treatment effect with a causal interpretation.
Although marginal methods can be robust to misspecification of the variance function or
dependence structure, they cannot protect against misspecification of the risk set. Hu and
others (2011) modeled the risk of recurrent hospitalizations, excluded individuals from the
risk set during each admission, and fitted generalizations of the Prentice and others (1981)
and Andersen and Gill (1982) models; since they were not interested in covariate effects
on the duration of hospitalizations they did not model this feature. When interest lies
in estimating the expected number of events over a period of follow-up or estimating the
effects of associated covariates, it can be useful to model the probability of being in the
symptom-free state which is obtainable from a more complete model for the onset and
resolution of exacerbations. In clinical trials, however, intensity-based models do not offer
a useful basis for causal inference when average treatment effects are the focus (Hernán
and Robins, 2016).
Our objective is to study the asymptotic and empirical biases when standard recurrent
event analyses (Andersen and others , 1993; Klein, 1992) are used in which individuals
are considered in the risk set during episodes. Through specification of an alternating
two-state process for the onset and resolution of exacerbations, we study the factors that
lead to biases in semiparametric rate-based models. In the model which accommodates
dependence in the risk for and duration of exacerbations we investigate the impact of the
dependence on standard analyses with the adjusted risk set.
The remainder of this Chapter is organized as follows. In Section 3.2 we define notation
and intensity functions for an alternating two-state process. In Section 3.3 we present the
Andersen-Gill model, the associated estimating functions and the large sample results
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for the estimated regression coefficients. The effect of misspecifying the risk set on the
limiting behaviour of estimators is derived in Section 3.4 for both the one-sample problem
and the regression setting. Section 3.4.1 considers the setting where the data are generated
according to a homogeneous two-state model while Section 3.4.1 considers the case where
there is heterogeneity in the risk for the onset and duration of exacerbations as well as
dependence between associated random effects. The application of rate-based models is
common in randomized clinical trials, so we study the implications on study power in
Section 3.5. An application to a clinical trial involving individuals with herpes simplex
virus infection is given in Section 3.6 and concluding remarks are made in Section 3.7.
3.2 Notation and an Alternating Two-state Model
Here we define a two-state which we consider as representing the underlying data generating
process in order to study and characterize the factors which determine the biases in rate-
based analyses.
Suppose individuals alternate between two states, a symptom-free state and a symp-
tomatic state. Let Zi(s) = 1 if individual i is symptom-free at s > 0, Zi(s) = 2 if they
are symptomatic, and suppose individuals start in state 1 at time t=0. Let Yij(s) =
I(Zi(s
−) = j), j = 1, 2. We let Sik and Tik denote the onset time and resolution time of
the kth exacerbation for individual i, and Wik = Tik − Sik be the duration of kth exacer-
bation k = 1, . . . . The counting process {Nij(u), 0 < u} records the cumulative number of
j → 3− j transitions they experienced over (0, t], j = 1, 2, where Ni1(t) =
∑∞
k=1 I(Sik ≤ t)
records the cumulative number of onset times which are often the events of interest which
interventions may be directed at preventing and Ni2(t) =
∑∞
k=1 I(Tik ≤ t) records the cu-
mulative number of resolution times; Ni(s) = (Ni1(s), Ni2(s))
′ is then a bivariate counting
process. Let Xi be a set of fixed covariates, and Hi(t) = {Ni(s), 0 < s < t,Xi}.
Let C denote fixed administrative censoring time, C†i a random censoring time, and
Ci = min(C,C
†
i ). We assume that the censoring process is independent of the event process




Ȳij(s)dNij(s). If N̄i(t) = (N̄i1(t), N̄i2(t))
′ then the complete history of the
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observation and event processes is H̄i(t) = {N̄i(s), Yi(s), 0 < s < t,Xi}. The complete
intensity function for j → 3− j transitions for individual i can then be written as
lim
∆t↓0
P (∆N̄ij(t) = 1|H̄i(t))
∆t
= Ȳij(t)λij(t|Hi(t)), j = 1, 2, (3.2.1)
under the condition of independence censoring (Kalbfleisch and Prentice, 2011).
Figure 3.1: A two-state diagram for chronic diseases with recurrent symptomatic episodes
Conditional on the censoring time, the probability of a particular sample path (Cook




















While likelihood based inference could be carried based on this specification our interest
lies primarily in the settings of clinical trials where intensity-based analyses are undesirable.
As pointed out by Kalbfleisch and Prentice (2011) conditioning on internal features of a life
history process is undesirable when evaluating the effects of interventions. We emphasize
therefore that the two-state model is to be used to derive limiting properties of estimators
arising from marginal recurrent event analyses which are widely used in the clinical trial
areas.
To study the potential bias of estimators arising from standard recurrent event analyses
when there are risk-free periods, we consider two risk-set definitions (RSD) depicted in
Figure 3.2. In RSD-A individuals are included in risk set for transitions from state 1 to state
2 event during symptomatic periods (i.e. Ȳ Ai (t) = Yi(t)); this represents a misspecification
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Figure 3.2: A schematic of a hypothetical timeline diagram with risk set definition (RSD)
A and B
of the risk set in the sense that individuals are not truly at risk for the event (onset of
episode) when they are in the midst of an episode an exacerbation. In RSD-B individuals
are excluded from the risk during symptomatic periods (i.e. Ȳ Bi (t) = Ȳi1(t) = Yi(t)Yi1(t)).
In many ways RSD-B seems sensible since it is in alignment with how these periods would be
treated in a multistate analysis. However in randomized clinical trials analyses are based on
estimating marginal features, and exclusion of individuals from the risk set based on their
status after randomization (which is possibly influenced by the treatment received) induces
confounding and thereby compromising the ability to make causal statements (Cook and
Lawless, 2018, Section 8.4). In the terminology of causal inference, whether an individual
is at risk or not of an exacerbation is a collider in the causal path for effects of treatment on
the onset of exacerbations (Cole and others , 2009; Hernán and Robins, 2016). In summary,
excluding individuals from the risk set when they are experiencing an excerbation seems
sensible since they truly are not at risk, but this precludes the ability to make direct causal
statements about marginal features that may be of interest. Retaining individuals in the
risk set is unnatural, but enables one to make a causal inference in a setting where the
treatment effect has a natural interpretation. These points motivate us to explore the
nature of biases induced when adopting the two approaches for defining the risk sets in
marginal rate-based analyses, which we do in the context of a plausible underlying model
for an alternating two-state process which we discuss in Section 3.4.
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3.3 Standard Recurrent Event Analyses
3.3.1 The Semiparametric Andersen-Gill Model
The semiparametric Andersen-Gill model (Andersen and Gill, 1982) is based on a working
Poisson model with a multiplicative covariate effect so that the rate function is given by
E(dNi1(t)|Hi(t)) = E(dNi1(t)|xi) = dR01(t) exp(x′iγ1)
where the baseline rate function dR01(t) is not specified to have any particular para-









Ȳ Ai (t){dNi1(t)− dRi1(t)}xi1 = 0 (3.3.2)
where dRi1(t) = dR01(t) exp(x
′
iγ1) and R01(t) =
∫ t
0
dR01(s)ds. Solving (3.3.1) with fixed γ1


































We obtain γ̂A1 by solving (3.3.4) and substitute γ̂
A



















These results correspond to the setting for which the AG method was intended: where
the events have no duration associated with them. Subject to the assumption of multi-
plicative covariate effects being correct this represents a valid analysis in such a setting.
More generally (i.e. when the events signal the onset of a symptomatic period.), however,
the properties of the resulting estimators have not been studied. If risk set definition B




3.3.2 Large Sample Robust Variance Formula and its Estimation
The estimating equations for the Andersen-Gill model are justified originally based on the
working assumption that the events are generated by a Poisson process. Robust variance
estimation is crucial, however, to provide protection from simple forms of model misspec-
ification within the class of multiplicative rate-based models (Lawless and Nadeau, 1995;
Lin and others , 2000). To obtain robust variance estimates, the model assumptions are
relaxed to be simply E(dNi1(t)|xi) = dR01(t) exp(x′iγ1). To accommodate different ways to
define the risk set, we use Ȳ hi (t) as the risk set indicator in the estimating equation (3.3.4)






















i for k = 1, 2, in which a
⊗
2 means aa′ and
a
⊗
1 = a, and a
⊗
0 represents a scalar 1. We let γ̂h1 be the solution to U
h(γ1) = 0, and let
γh1 denote its limiting value which is determined by the solution to E[U
h(γ1)] = 0 where
the expectation is taken with respect to the true model. By adopting working model













where dMhi1(t) = Ȳ
h
i (t){dNi1(t)− dR01(t) exp(x′i1γ1)}. Since Ȳ hi (t) is a predictable process






















and s(k,h)(t) = E[S(k,h)(γ1, t)] where here the expectation is taken with respect to the
model given in Section 3.2. Since n1/2(γ̂h1 −γh1 ) ' A−1(γh1 )n−1/2U(γh1 ) by Taylor expansion,

















The robust varianceA−1(γh1 )B(γh1 )A−1(γh1 ) is empirically estimated by Â−1(γ̂h1 )B̂(γ̂h1 )Â−1(γ̂h1 )














































and dM̂hi1(t) = Ȳ
h
i (t){dNi1(t)−dR̂h01(t) exp(xiγ̂h1 )} where dR̂h01(t) is the estimate of dR01(t)
based on the RSD-h for h = A,B. Then
âsvar(n1/2(γ̂h1 − γh1 )) = Â−1(γ̂h1 )B̂(γ̂h1 )Â−1(γ̂h1 )
is used as a basis for inference.
3.4 Bias in Estimation of Mean Function and Regres-
sion Coefficients
Here we investigate the asymptotic bias of estimators under independent censoring when
the marginal estimating equation is based on the Andersen-Gill model with a working in-
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dependence assumption. We consider settings involving: a Markov/semi-Markov model for
the onset and duration of recurrent exacerbations (Section 3.4.1), and a mixed model with
dependent bivariate random effects modulating the baseline transition intensities (Section
3.4.2). Under each scenario, we obtain the asymptotic bias of the estimated mean function
and the regression coefficients under the Andersen-Gill model.
3.4.1 Risk-set Misspecification in a Markov/Semi-Markov Model
When the intensity for the onset of exacerbations is based on a Markov model (3.2.1)
reduces to the form
lim
∆t↓0
P (∆N̄i1(t) = 1|H̄i(t))
∆t
= Ȳi1(t)λi1(t), (3.4.1)
where t is a total time (calendar time). If the resolution of exacerbations is governed by a
semi-Markov model we obtain
lim
∆t↓0
P (∆N̄i2(t) = 1|H̄i(t))
∆t
= Ȳi2(t)λi2(Bi(t)) (3.4.2)
where Bi(t) = t− SNi1(t−) is the time since symptom onset. For this specific investigation,
we assume a time-homogeneous Poisson model for the onset of exacerbations and that
exacerbation durations follow a Gamma distribution. Hu and others (2011) examined the
asymptotic properties and convergence to the true value in the RSD-B setting so we focus
on the asymptotic bias in RSD-A.
Marginal Rate and Mean Function Estimates
We consider the setting with no covariates first. In this case we have a single rate function
estimate of interest dR01(t) and we consider a simplified version of (3.3.1) with a general
at risk indicator Ȳ Ai (t):
m∑
i=1
Ȳ Ai (t){dNi(t)− dR01(t)}
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Taking the expectation of a single individual’s contribution gives
E[Ȳ Ai (t)(dNi1(t)− dR01(t))] = E[E[Ȳ Ai (t)(dNi1(t)− dR01(t))|Ȳ Ai (t)]]
= P (Ȳ Ai (t) = 1)(E[dNi1(t)|Ȳ Ai (t) = 1]− dR01(t)). (3.4.3)
where the expectations and probabilities are computed based on the full model given in
(3.3.1) under the assumptions in (3.4.1) and (3.4.2). We assume that the true transition
intensity function λi1(t) is time-homogeneous so that let λi1(t) = λ01 and under completely
independent censoring, equation (3.4.3) has solution
dRA01(t) = P (Yi1(t) = 1)λ01dt (3.4.4)
and we note that RA01(t) =
∫ t
0
dRA01(s) is the mean function for the counting process
{Ni1(u), 0 < u}. The standard Nelson-Aalen estimator with RSD-A is consistent for the
cumulative mean function under independent right censoring (Nelson, 1995; Lawless and
Nadeau, 1995). It is therefore reasonable to use the Nelson-Aalen estimate when including
individuals in the risk set to estimate the expected number of exacerbations. However,
the estimator R̂A01(t) will be asymptotically biased (conservative) for the true cumulative
intensity (rate) function Λ01(t) =
∫ t
0
λ01ds = λ01t. In other words, if P (Yi1(t) = 1) is small
(i.e. if there is a high probability of being in the exacerbation state) the bias can get large.
Since we assume that Wik ∼ GAM(2, λ02) and using the fact that a Gamma random vari-
able can be represented as a sum of independent exponential random variables we can use
this to calculate P (Yi1(t) = 1). The details of the calculation of P (Yi1(t) = 1) is given in
Appendix 3.A for a particular model with a Gamma distributed sojourn time distribution
in state 2. We note that when t ↑ ∞, P (Yi1(t) = 1) converges to λ02/(2λ01 + λ02) for
the one sample problem. Figure 3.3 shows that the asymptotic bias of the Nelson-Aalen
estimators decreases when the mean sojourn time in the exacerbation state decreases, in
which case the effect of misspecification of the risk set is reduced.
48













LIMITING VALUE OF NA
TRUE CUMULATIVE BASELINE HAZARD
































Figure 3.3: The limiting values and the asymptotic bias of Nelson-Aalen estimator under
the RSD-A setting as a function of t with E(Wik) = 0.1 (left panel) and as a function of
E(Wik) at t=2 (right panel) at fixed values of λ01 = 2, C=2, and 20% random censoring
Estimation in the Regression Setting
If we consider covariates, the expectation of the estimating equation (3.3.1) is given by∫
xi
P (Ȳ hi (t) = 1|xi){Eh[dNi1(t)|Ȳ hi (t) = 1, xi]− dRi1(t)}f(xi)dxi = 0 (3.4.5)
where here this is taken with respect to the model given by (3.4.1) and (3.4.2). The
proportional rate model with RSD-A does not account for the duration of exacerbations,
so it is worthwhile to consider the asymptotic bias for γ̂A1 . In the sequel, we examine the
limiting value, and asymptotic bias of R̂A01(t), and γ̂
A
1 .
Consider a randomized clinical trial where Xi is a binary variable with P (Xi = 0) =






1 ) denote the value to which dR̂i1(t)





x=0 P (xi = x)P (Yi1(t) = 1|x)λ01 exp(xβ1)dt∑1





The limiting value of γ̂A1 , denoted by γ
A








du = 0, (3.4.7)
where we define s(k,A)(u) = E[Ȳ Ai (t)x
k
i dNi1(u)], and s









P (xi)P (Ȳi1(t) = 1|xi)λ01(t) exp(xiβ1), (3.4.8)
s(1,A)(t) = P (xi = 1)P (Ȳi1(t) = 1|xi = 1)λ01(t) exp(β1), (3.4.9)
s
(0,A)
1 (γ1, t) =
1∑
xi=0
P (Yi(t) = 1)P (xi) exp(xiγ1),
s
(1,A)
1 (γ1, t) = P (xi = 1)P (Yi(t) = 1) exp(γ1).
Note that s(k,A)(t) = s(k,B)(t). If we solve (3.4.7), we obtain
γA1 = β1 + log
(∫∞
0
P (Ȳi1(u) = 1|xi = 1)du∫∞
0
P (Ȳi1(u) = 1|xi = 0)du
)
, (3.4.10)
where the detail of derivation is presented in Appendix 3.B. Here we assume the multi-
plicative model under the time-homogeneous assumption in (3.4.1) in which λi1(t|xi) =
λ01 exp(x
′
iβ1), and we assume Wik ∼ GAM(2, λ02 exp(x′iβ2)) where Wik is the duration of
kth exacerbation. It suggests that in addition to the baseline functions, the magnitude of β1
and β2 determines the asymptotic bias of γ̂
A
1 since P (Ȳi1(t) = 1|xi) is a function of λi1(t|xi)
and λi2(t|xi). The limiting value of robust covariance matrix is A−1(γA1 )B(γA1 )A−1(γA1 ) the
calculation of which is presented in Appendix 3.B.
Figure 3.4a shows that the asymptotic biases of coefficient decreases as the mean sojourn
time for the exacerbation decreases under the setting λ01 = 2, β1 = log(0.75), and β2 =
log(1.25) with C=2 and 20% random censoring. Even though the asymptotic bias becomes
50























































Figure 3.4: The asymptotic bias of a coefficient under the Andersen-Gill model with RSD-
A as a function of E(Wik|Xi = 0) (panel a), and β2−β1 (panel b) at fixed values of λ01 = 2,
and β1 = log(0.75) with C = 2, and 20% random censoring
smaller, it does not converge to the true value. Figure 3.4b shows how the limiting value
changes as a function of β2 − β1 in the setting where λ01 = 2,E(Wik|Xi = 0) = 0.1
(λ02 = 20), β1 = log(0.75). The sign of bias for the coefficients depends on the difference
between β1 and β2. If treatment significantly reduces the risk of the exacerbation and
shortens the duration of symptoms, the misspecification of the risk set will lead to an
underestimation of the treatment effect.
Simulation Studies
Simulation studies were conducted to examine the empirical bias and the performance
of the robust variance estimator under misspecification of the risk set. To be specific
the data are generated according to the two-state model in order for the data to rep-
resent that arising from episodic conditions. we are primarily interested in the perfor-
mance of the AG type analyses with the original formulation using RSD-A and using
the modified RSD-B to correspond to the common ad hoc approach for dealing with the
duration of the episode and use of the AG model formulation. We set λ01 = 2, and
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β1 = log(0.75) where λi1(t|xi) = λ01 exp(xiβ1), E[Wik|xi = 0] = 0.1, 0.25, and 0.5 where
Wik|xi ∼ GAM(2, λ02 exp(xiβ2)). We also set C=2 and introduced 20% random censoring
with a sample of size m = 1000 and a total of nsim = 1000 samples simulated. For in-
dividual i, we generate Si1 ∼ EXP (λ01 exp(xiβ1)) followed by Ti1 = Si1 + Wi1 where Wi1
is generated by GAM(2, λ02 exp(xiβ2)). For j > 1, we generate Sij|Sij > Tij by truncated
exponential distribution with rate λ01 exp(xiβ1) and Wik ∼ GAM(2, λ02 exp(xiβ2)). We
repeat this until either Sij > Ci or Tij > Ci for j = 1, . . . with a censoring time Ci. The
results are reported in Table 3.1 under the RSD-A and RSD-B setting.
As expected from the asymptotic calculations the empirical bias of the estimated re-
gression coefficients under RSD-A is positive when β1 < β2. This is because the positive
effect of β2 on the resolution of the exacerbation is reflected by the effect of β1 resulting in
β̂1 increasing. In other words, the average treatment effect under RSD-A in the spirit of
causal inference is attenuated by the positive treatment effect for the resolution of disease.
When β1 = β2, the empirical bias is low. Thus misspecification of the risk set is a signifi-
cant matter if interest lies in the estimates of treatment effects. In a biological sense, the
mechanism of occurrence and resolution of exacerbations may be different and it requires
to reckon with a target of intrinsic treatment effects. Therefore, it needs caution to make
a simple causal statement in this spirit. Interestingly, the use of a robust standard error
induces lower empirical coverage probabilities than that of naive standard error since in
this case the robust standard error is smaller than the naive standard error. From the
formula of asymptotic variance in Appendix 3.C, when we use RSD-A, A(γA1 ) = BA1 and
BA3 = B
A
4 , which means B(γB1 ) = A(γA1 ) + BA2 − BA4 . However, BA2 < BA4 with RSD-A
because E(dNi1(s)dNi1(t)|xi, Ȳ Ai (s) = 1, Ȳ Ai (t) = 1) in BA2 conditions that a subject should
be at risk and in the exacerbation-free state at s and t where the exacerbation occurs at s,
which implies that there is a transition from state 1 to 2 at s and another transition occurs




4 only condition on being
at risk and in the exacerbation-free state at s and t, separately. Thus, A(γA1 ) > B(γA1 )
so that the naive standard error is greater than the robust standard error. Robust vari-
ance estimates ensure protection against model misspecification provided the rate function
is correctly specified. However, if the risk set is misspecified inconsistent estimates are































































































































































































































































































































































































































































































































































































































































































































































































































misspecification. As a result, the misspecification of risk set leads to significant biases
and serious departure of empirical coverage probabilities. With RSD-B, the estimates of
coefficients converge to the true value as indicated in Hu and others (2011).
3.4.2 Misspecification under Heterogeneity and Dependence
When there exists heterogeneity in the risk of exacerbation and the sojourn time distribu-
tion in the exacerbation state, a dependence between the two counting processes can be
introduced. These features are typically ignored in recurrent event analyses so we further
investigate the asymptotic bias of the Andersen-Gill estimators in this setting.
Suppose Ui = (Ui1, Ui2)
′ is a bivariate random effect for an alternating process so that










P (∆N̄i2(t) = 1|H̄i(t), ui)
∆t
= ui2Ȳi2(t)λi2(Bi(t))
where Uij is gamma distributed with E(Uij) = 1 and Var(Uij) = φj, for j = 1, 2 with the
bivariate p.d.f g(Ui).
Marginal Rate and Mean Function Estimates
In the absence of covariates, we assume λi1(t) = ui1λ01 and Wik ∼ GAM(2, ui2λ02). Then
(3.4.4) becomes
dRh01(t) = E
h(Ui1|Ȳ hi (t) = 1)λ01dt (3.4.11)










ui1g(ui)P (Yi1(t) = 1|ui)dui1dui2,
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g(ui)P (Yi1(t) = 1|ui)
P (Yi1(t) = 1)
dui1dui2,
where





g(ui)P (Yi1(t) = 1|ui)dui1dui2.
We obtain P (Yi1(t) = 1|ui) from the formula (3.A.2) or (3.A.3) in Appendix 3.A by re-
placing λ01 and λ02 with ui1λ01 and ui2λ02, respectively.
Figure 3.5a shows the limiting value of cumulative baseline function over the window (0,2]
with 20% random censoring, λ01 = 2,E[Wik|xi = 0] = 0.25. The true cumulative baseline
hazard indicates Λ01(t) = λ01t. Figure 3.5b shows the asymptotic bias of cumulative
baseline function at t=2 with 20% random censoring, λ01 = 2 as a function of the mean
sojourn time in the exacerbation state. In both settings, we assume that Uij is gamma
distributed with mean 1 and variance φj = 0.4 for j = 1, 2 and we link Ui1 and Ui2
with the Gaussian copula having Kendall’s τ=-0.25, 0, and 0.25. Here the cumulative
mean function is not equal to the cumulative intensity function due to symptom duration.
We note that RA01(t = 2) and R
B
01(t = 2) are smaller than the true value of cumulative
intensity function Λ01(t = 2) and the bias also decreases as Kendall’s τ increases; a strong
positive association between Ui1 and Ui2 implies that the duration of exacerbations tends to
decrease as the risk of exacerbations increases. As the mean sojourn time for exacerbations
increases the bias increases in both RSD-A and RSD-B settings. Also, the use of RSD-B
yields smaller bias than that of RSD-A. The Nelson-Aalen estimate with RSD-B shows a
little departure from the true cumulative baseline hazard where the bias arises because of
the impact of model misspecification in terms of individual heterogeneity and dependence
between random effects for an alternating process.
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Figure 3.5: The limiting value of the Nelson-Aalen estimate and the true cumulative base-
line hazard under dependence sojourn time models due to correlated random effects
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NEGATIVE DEPENDENCE (τ = − 0.25)
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POSITIVE DEPENDENCE (τ = 0.25)
TRUE CUMULATIVE BASELINE HAZARD
(a) Setting: λ01 = 2,E[Wik|xi = 0] = 0.25, φ1 = φ2 = 0.4 with the Gaussian copula and
C = 2, r† = 20%
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NEGATIVE DEPENDENCE (τ = − 0.25)
INDEPENDENCE (τ = 0)
POSITIVE DEPENDENCE (τ = 0.25)
(b) Setting: λ01 = 2, φ1 = φ2 = 0.4 with the Gaussian copula and C = 2, r
† = 20%
Estimation in the Regression Setting
With covariates, we assume λi1(t|ui1, xi) = ui1λ01 exp(β1) andWik|ui2, xi ∼ GAM(2, ui2λ02 exp(β2)).
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i (t) = 1|xi)Eh[Ui1|Ȳ hi (t) = 1, xi]λ01 exp(xiβ1)∑1
xi=0
P (xi)P (Ȳ hi (t) = 1|xi) exp(xiγh1 )
for h = A,B under a randomized clinical trial, where Xi is a binary variable with P (Xi =
0) = P (Xi = 1) = 0.5. The limiting value γ
h
1 for h = A,B can then be obtained by solving






i (t) = 1|xi)Eh[Ui1|Ȳ hi (t) = 1, xi]λ01(t) exp(xiβ1),
s(1,h)(t) = P (xi = 1)P (Ȳ
h
i (t) = 1|xi = 1)Eh[Ui1|Ȳ hi (t) = 1, xi = 1]λ01(t) exp(β1),
s
(0,h)





i (t) = 1|xi) exp(xiγ1),
s
(1,h)
1 (γ1, t) = P (xi = 1)P (Ȳ
h
i (t) = 1|xi = 1) exp(γ1),
for h = A,B. Note that s(k,A)(t) = s(k,B)(t). We can simplify γA1 here as
γA1 = β1 + log
(∫∞
0
P (Ȳ Ai (u) = 1)E
A[Ui1|Ȳ Ai (u) = 1, xi = 1]du∫∞
0
P (Ȳ Ai (u) = 1)E
A[Ui1|Ȳ Ai (u) = 1, xi = 0]du
)
.
Likewise, the limiting value of the covariance estimator is given as A−1(γh1 )B(γh1 )A−1(γh1 )
and the estimated variance is Â−1(γ̂h1 )B̂(γ̂
h
1 )Â
−1(γ̂h1 ) as shown in Section 3.3.2.
Figure 3.6 display the the asymptotic bias of regression coefficient γA, γB when the
Andersen-Gill model is fitted. The bigger the mean sojourn time in the exacerbation
state, the larger the bias is. For the second setting with β1 < 0, the bias increases as β2 is
farther from β1 and when β2 > β1, the bias is positive. Therefore, the effect of treatment
for the risk of disease occurrence may be reduced if treatment decreases the occurrence of
episodes and increases the recovery of episode under the Andersen-Gill model. Note that
as Kendall’s τ increases, the bias decreases.
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Figure 3.6: The asymptotic bias of γA and γB under the Andersen-Gill model for RSD-A
and RSD-B with different β2, E(Wik) and Kendall’s τ
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(a) Setting: λ01 = 2, β1 = log(0.75), β2 = log(1.25), φ1 = φ2 = 0.4, Kendall’s τ =
−0.25, 0, 0.25 and C = 2, r† = 20%
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(b) Setting: λ01 = 2,E[Wik|xi = 0] = 0.25, β1 = log(0.75), φ1 = φ2 = 0.4, Kendall’s























































(c) Setting: λ01 = 2,E[Wik|xi = 0] = 0.25, β1 = log(0.75), β2 = log(1.25), φ1 = φ2 = 0.4,
and C = 2, r† = 20%
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We conduct simulation studies to study the empirical bias and the performance of
robust variance arising from the misspecification of risk set as well as frailty and dependence
between alternating processes. The data is generated based on correlated random effects via
a copula model. We set λ01 = 2, β1 = log(0.75) where λi1(t|Hi(t), ui) = ui1λ01 exp(xiβ1),
E(Wik|xi = 0) = 0.1, 0.25, and 0.5 where Wik|ui, xi ∼ GAM(2, ui2λ02 exp(xiβ2)), and Uij
is gamma distributed with E(Uij) = 1,Var(Uij) = 0.4 for j = 1, 2. We use the Gaussian
copula with Kendall’s τ=-0.25, 0.00, and 0.25 for the bivariate distribution of Ui. We also
set the administrative censoring time C=2, 20% random censoring with m=1000, and a
total of 1000 samples were simulated. The results are reported in Table 3.2 under the
RSD-A and RSD-B setting.
Table 3.2 shows that the means of estimated coefficients are almost equal to their lim-
iting values. It is apparent that the impact of using an incorrect definition of the risk set
can be appreciable, consistent with the result in Table 3.1. However, no concern of de-
pendence between two alternating processes yields bias under the correct risk set RSD-B.
As we observed in Figure 3.6, the bias decreases as Kendall’s τ increases, the longer the
mean sojourn time and the farther β2 from β1 the bigger the bias. There are differences
between the naive standard errors and robust standard errors due to the model misspeci-
fication from the true model, but there is good agreement between the empirical standard
error and the average robust standard error compared to the average naive standard error.
Under the “correct” RSD-B, the robust variance estimates performed fairly well compared
to the naive variance estimates although the empirical coverage probabilities are not in
acceptable range when E[Wik|xi = 0] is appreciable. However, the robust standard errors
do not guarantee the protection against the misspecification of the risk indicator. When
RSD-A is used, a serious bias and lower coverage probabilities are obtained in this setting.









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.5 Impact of the Episode Duration Distribution on
Power
We previously examined the impact of misspecification of risk set on point estimates and the
asymptotic variance of estimates. In this section we explore the impact of misspecification
of the risk set on study power.
Consider the design of a randomized trial with recurrent responses. At the design stage,
we assume a mixed Poisson model and calculate a sample size based on λi1(t|ui1, Hi(t)) =
ui1λ01 exp(β1xi) with Ui1 ∼ Gamma(1/φ1, 1/φ1) (Cook and Lawless, 2007). If we want
to test if an intervention has an effect on event occurrence we test H0 : β1 = β10 = 0
vs. HA : β1 = β1A. However, the true underlying model requires one to consider the
exacerbation duration. Hence interest lies in the change of power due to the duration of
the exacerbation as well as the association between the occurrence of exacerbation and the
recovery of exacerbation. As previous sections, we consider the Andersen-Gill model with
a robust standard error with RSD-A and RSD-B for analysis and use the two-sided Wald
test.
Suppose we consider the hypotheses H0 : β1 = β10 = 0 vs. HA : β1 = β1A = log(0.75)
under a two-sided test at the α1 = 0.05 level of significance and the power of 1−α2 = 0.8.
Assume λ01 = 2, φ1 = 0.4 and a randomized trial gives P (Xi = 1) = P (Xi = 0) = 0.5.
















where zp represents the (1 − p)-quantile for a standard normal distribution. asvar0(·)








P (Xi = xi)E
[
λ01 exp(β1xi)Ci




Table 3.3: Empirical rejection rates for tests of treatment for occurrence of exacerbations
where sample size is estimated based on the mixed Poisson model with E[N̄i1(2)|xi = 0] =
4, φ1 = 0.4, β10 = 0, β1A = log(0.75), E(Wik|xi = 0)=0.10, 0.25, and 0.50, φ2 = 0.4 and
Kendall’s tau -0.25, 0, and 0.25 over (0,2] with 20% random censoring, nsim = 2000
τ=-0.25 τ = 0 τ = 0.25
β2 E(Wik|xi = 0) RSD-A RSD-B RSD-A RSD-B RSD-A RSD-B
log(0.75) 0.10 92.1 81.5 88.2 79.4 85.8 79.1
0.25 96.8 80.3 93.1 79.0 90.5 78.0
0.50 97.2 72.4 95.4 72.3 92.3 73.2
0 0.10 77.4 77.8 73.5 77.1 72.6 77.0
0.25 66.5 73.5 60.7 74.1 59.5 75.5
0.50 34.5 64.4 34.2 67.7 30.9 67.8
log(1.25) 0.10 60.0 72.8 61.2 75.0 61.3 76.6
0.25 28.3 68.7 29.7 69.5 30.6 73.1
0.50 5.9 58.6 5.1 61.2 5.3 62.9
We next conduct simulation studies to investigate the impact of a misspecifed risk
set and heterogeneity on power with the sample size calculated based on (3.5.1) where
E[N̄i1(2)] = 4 with φ1 = 0.4 and 20% random censoring under the mixed Poisson model.
We simulated data from a conditionally the Markov/semi-Markov model with correlated
random effects via a copula model with the calculated sample size where E[N̄i1(2)] = 4 is
fixed and φ1 = φ2 = 0.4. We consider different mean sojourn times for exacerbation state
in the control arm of E(Wik|xi = 0) = 0.1, 0.25, 0.5 and different Kendall’s τ=-0.25, 0, and
0.25.
63
Figure 3.7: Power curves based on RSD-A (left panel) and RSD-B (right panel) with
Kendall’s τ -0.25, 0, and 0.25 where the sample size is calculated based on the mixed
Poisson model with E[N̄i1(2)|xi = 0] = 4, β10 = 0, β1A = log(0.75), φ1 = 0.4, φ2 = 0.4
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With the generated data, we fit the Andersen-Gill model using RSD-A and RSD-B and
conduct the hypothesis testing using robust standard errors based on a two-sided Wald
test. A total number of 2000 replicates were generated and the empirical rejection rates
(REJ%), defined as the percentage of replicates leading to rejection of the null hypothesis
were computed; see Table 3.3.
The power decreases as the mean sojourn time for exacerbation-state increases for the
settings with β1 6= β2. It is worth noting that the power significantly depends on the
value of β2 with RSD-A; as β2 is farther from the β1 the loss in power increases. Note
that when β1 = β2 we observe overpower with RSD-A. Using RSD-B reduces loss in power
compared to RSD-A. As Kendall’s τ increases there is a greater loss in power when β2 = 0
under RSD-A. When β1 6= β2, the increase in Kendall’s τ decreases loss in power under
the RSD-B.
Figure 3.7 shows power curves with the same setting as the empirical study. The effect
of Kendall’s τ on power relies on the mean sojourn time in the exacerbation-free state and
the value of β2. When β1 6= β2, the increase in the mean sojourn time in the exacerbation-
state reduces power, however, when β1 = β2 power is greater than 80% with RSD-A. The
loss in power with RSD-B is smaller than the one with RSD-A when β1 6= β2.
3.6 Application to a Herpes Simplex Trial
Herpes simplex is an infectious disease resulting in blisters on the infected part of the body.
We consider the data from Romanowski and others (2003) who conducted a randomized
two-period crossover trial to examine the effect of suppressive therapy versus episodic
therapy. Here we only consider the first 24-week study period, therefore, each patients
only had one treatment, suppressive or episodic therapy. We also include sex (female vs.
male), virus type (HSV1 or HSV2) as covariates in addition to treatment (episodic therapy
vs. suppressive therapy). In Table 3.4, we report on analyses of herpes simplex study using
the Andersen-Gill model with RSD-A and RSD-B described in 3.3.1, respectively .
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Table 3.4: Analysis of occurrence of herpes simplex using RSD-A and RSD-B based
on the Andersen-Gill model
RSD-A (Ȳ Ai (t) = Yi(t)) RSD-B (Ȳ
B
i (t) = Yi(t)Yi1(t))
Covariate EST SE1 SE2 p3 EST SE1 SE2 p3
Treatment -1.875 0.200 0.240 < 0.001 -1.871 0.145 0.186 < 0.001
Sex -0.189 0.135 0.173 0.276 -0.303 0.115 0.166 0.067
Virus Type 0.159 0.121 0.146 0.277 0.071 0.107 0.148 0.632
1 Naive standard error
2 Robust standard error
3 p-values based on robust standard error






































Figure 3.8: Cumulative baseline rate function with RSD-A (Inclusion) and RSD-B (Exclu-
sion)
First of all, treatment has a significant effect on the occurrence of herpes simplex with
both RSD-A (RR = 0.15; 95% CI: -2.35, -1.40; p < 0.001), RSD-B (RR = 0.15; 95%
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CI: -2.24, -1.51; p < 0.001), where two estimates are in very close agreement. Whereas
the estimates for sex with RSD-A (RR = 0.83; 95% CI: -0.53, 0.15; p = 0.276) differ
from the one with RSD-B (RR = 0.74; 95% CI: -0.63, 0.02; p = 0.067). Also there
are differences in the estimates for virus type between RSD-A (RR = 1.17; 95% CI: -
0.13, 0.45; p = 0.277) and RSD-B (RR = 1.07; 95% CI: -0.22, 0.36; p = 0.632). These
differences arise due to the impact of misspecification of risk set. We also note that the
naive standard errors and robust standard errors are not identical, which tells that there
is heterogeneity between subjects and possible dependence between the onset and recovery
of episode processes. Figure 3.8 contains a plot of the estimated cumulative baseline rate
function with the Andersen-Gill analysis based on RSD-A and RSD-B. The slope of the
cumulative baseline rate function with RSD-B is slightly greater than the one with RSD-A,
suggestive of a higher rate for the occurrence of outbreaks with RSD-B than RSD-A (Cook
and Lawless, 2007, Chapter 5, p. 177). However, the median of duration of episodes is
5 days indicating a short duration of episodes, therefore, the impact of misspecification
of risk set on the estimate of cumulative baseline rate function is small. Note that with
RSD-A, the cumulative baseline rate function can be naively interpreted as an estimate of
the cumulative baseline mean function.
3.7 Discussion
In this Chapter we have pointed out that estimators of mean function and covariate effects
from the naive use of the Andersen-Gill model (Andersen and others , 1993) are sensitive
to the handling of risk-free periods as well as strength of the association between the
onset and duration of episodic events. Misspecification of at risk indicators can lead to
inconsistent estimators of regression coefficients and the use of robust standard errors does
not guarantee protection against misspecification of the duration dependent processes. The
biases we refer to for the mean function are specified in relation to the cumulative intensity
for the onset of episodes, or the actual mean function reflected the expected number of
events over time. In the regression setting we refer to the bias of estimators of the regression
coefficient for the transition intensity for the onset of episodes.
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Full specification of the intensities for an alternating two-state process is challenging in
practice and it is impossible to achieve robustness in this framework since correct model
specification is required to ensure the partial likelihood estimating equations are unbiased.
Causal inference can be based on the expected number of events at a land-mark time or
based on proportional rate function models but there is a tension between the need for
full specification of models to advance scientific understanding and the need for simple
models supporting causal conclusions. Lee and Cook (2018) develop a model for a mixed
two-state process for characterizing recurrent episodic conditions which features a Markov
time-scale for the onset of exacerbations and a semi-Markov time-scale for the duration of
the exacerbations. Correlated random effects enable one to assess the need to accommodate
heterogeneity and allow for a dependence between the sojourn times in the exacerbation
state and the risk for the onset of events.
When mortality rates are appreciable, as is the case among individuals with advanced
chronic obstructive pulmonary disease, it is considerably more challenging to model the
onset and duration of exacerbations and summarize the effects of interventions. In the
multistate framework an absorbing state representing death can be added, and random
effects can be considered in the intensities for death. However expressing treatment effects
robustly on the onset of exacerbations is very challenging. Much work has been carried out
in this area for recurrent transient events (Cook and Lawless, 1997; Ghosh and Lin, 2000,
2002) but utility-based analyses may be preferable when events have a duration associated
with them (Cook and others , 2003).
An alternative approach in these more complex settings is to focus on estimation of state
occupancy probabilities using nonparametric methods. Cook and Lawless (2018, Sections
3.4 and 4.3) discuss this for one-sample problems and consider marginal regression models
for state occupancy probabilities based on direct binomial regression (Scheike and others ,
2008). Utility-based analyses are also of possible value (Cook and others , 2003, Cook and
Lawless, 2018, Section 8.1). These and other marginal quantities, such as features of state
entry time or sojourn time distributions, may offer a more convenient basis for causal
inference since they are not defined inherently in terms of conditional probabilities. As
always, the choice of the estimand must be made based on interpretation and it must be
meaningful for the problem at hand. Inverse probability weighting can often be useful to
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correct for some selection biases and confounding.
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Appendix 3.A: Computation of State Occupancy Prob-
abilities
P (Yi1(t) = 1|xi) is difficult to calculate under the assumption of semi-Markov model,
especially when the distribution of the duration of exacerbations is not exponential. Here,
we decompose state 2 into two states to exploit the property of Gamma distribution which
can be expressed as a sum of exponential distribution. We define a new state process
{Z̄(t), 0 < t} on the extended state space {1, 2A, 2B} (Cook and others , 2009), and let
Z(t) = 1 if Z̄(t) = 1 and Z(t) = 2 if Z̄(t) = 2A or Z̄(t) = 2B as shown in Figure 3.9.
Then, P (Yi1(t) = 1|xi) can be expressed by




P (Z̄(t) = r|Z̄(0) = 1, xi) = P (Z̄(t) = 1|Z̄(0) = 1, xi).
Figure 3.9: State diagram for recurrent exacerbations with extended Markov models
The term P (Z̄(t) = 1|Z̄(0) = 1, xi) is calculated by the transition probability ma-
trix P(0, t|xi) = P(t|xi) = [pij(t|xi)], for i, j = 1, 2A, 2B. Here we consider the time-
homogeneous case. We assume that the duration of the kth exacerbation is Wik = Wik2A +
Wik2B where Wikl ∼ EXP (λi2) for l = 2A, 2B and Wik2A ⊥ Wik2B, so Wik ∼ GAM(2, λi2).
Under the multiplicative model, we let λi1 = λ01 exp(xiβ1) and λi2 = λ02 exp(xiβ2). It is
noted that there is a common covariate for the development and resolution of exacerba-
tions. The time-homogeneous transition intensity matrix of {Z̄(t), 0 < t} on state space
70







We let P12A(t) = P (Z̄(t) = 2A|Z̄(0) = 1, xi), P12B(t) = P (Z̄(t) = 2B|Z̄(0) = 1, xi), and
P11(t) = P (Z̄(t) = 1|Z̄(0) = 1, xi). Using the Kolmogorov forward equations (Cox and
Miller, 1965), we note
P ′12A(t) = −λi2P12A(t) + λi1P11(t)
P ′12B(t) = λi2P12A(t)− λi2P12B(t)
P ′11(t) = λi2P12B(t)− λi1P11(t)
P12A(t) + P12B(t) + P11(t) = 1, P11(0) = 1 (3.A.1)

















where a = λi1/2 + λi2 and b =
√
λi1λi2 − (λi1)2/4. If λi1 − λi2/4 > 0 it can be written as







































Appendix 3.B: Calculation of Asymptotic Bias of γ̂A1





in (3.4.10). By plugging s(0,A)(u), s(1,A)(u),
s(0,A)(γ1, u), and s
(1,A)(γ1, u) into (3.4.7), we have∫ ∞
0
{




P (Ȳi1(u) = 1|xi = 1)λ01 exp(β1)









P (Ȳi1(u) = 1|xi = 1)λ01 exp(β1)du∫∞
0
(








P (Ȳi1(u) = 1|xi = 1)du∫∞
0
P (Ȳi1(u) = 1|xi = 0)du
,
which has the final form as (3.4.10) by taking log() for both sides.
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Appendix 3.C: Derivation of The Sandwich Covariance
Matrix
Let dMhi1(t) = Ȳ
h
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In Section 3.4.1 and under the assumption of time-homogeneous rate function for the
two processes,
E(dN2i1(t)|xi, Ȳ Ai (t) = 1) = E(dNi1(t)|xi, Ȳ Ai (t)) = P (Yi1(t) = 1|xi)λ01 exp(xiβ1),
and
E(dNi1(s)dNi1(t)|xi, Ȳ Ai (s) = 1, Ȳ Ai (t) = 1)
= P (Z̄i(s
−) = 1|Z̄i(0) = 1, xi)P (Z̄i(t−) = 1|Z̄i(s) = 2, xi)λ201 exp(2xiβ1)
for s < t, where P (Yi1(t) = 1|xi) = P (Z̄i(t−) = 1|Z̄i(0) = 1, x1), and P (Z̄i(t−) = 1|Z̄i(s) =
2, xi) is given in Appendix 3.A. In the setting of Section 3.4.2 with dependent random
effects,






ui1P (Yi1(t) = 1|ui, xi)λ01(t) exp(xiβ1)dG(ui),





−) = 1|Z̄i(0) = 1, xi, ui)P (Z̄i(t−) = 1|Z̄i(s) = 2, xi, ui)λ201 exp(2xiβ1)dG(ui)
for s < t. Moreover
E(dN2i1(t)|xi, Ȳ Bi (t) = 1) =
E(dN2i1(t)|xi, Ȳ Ai (t) = 1)
P (Yi1(t) = 1|xi)
,
and
E(dNi1(s)dNi1(t)|xi, Ȳ Bi (s) = 1, Ȳ Bi (t) = 1) =
E(dNi1(s)dNi1(t)|xi, Ȳ Ai (s) = 1, Ȳ Ai (t) = 1)
P (Yi1(s) = 1, Yi1(t) = 1|xi)
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−) = 1|Z̄i(0) = 1, xi, ui)P (Z̄i(t−) = 1|Z̄i(s) = 2, xi, ui)dui1dui2λ01 exp(xiβ1)
P (Yi1(s) = 1, Yi1(t) = 1|xi)





−) = 1|Z̄i(0) = 1, xi, ui)P (Z̄i(t−) = 1|Z̄i(s) = 1, xi, ui)dui1dui2λ01 exp(xiβ1)
P (Yi1(s) = 1, Yi1(t) = 1|xi)








In many chronic diseases individuals are at risk of several distinct types of potentially
recurring events. In asthma, for example, individuals are at risk of different types of
recurrent exacerbations (Jayaram and others , 2006), individuals with diabetes are at risk
recurrent complications in eyes and kidneys (The Diabetes Control and Complications Trial
Research Group, 1986), and cancer patients are at risk of metastases in different locations
of the body (Hortobagyi, 1998). In public health studies there is interest in modeling
the occurrence of different kinds of infections in populations at risk such as children in
developing countries (Lemaire and others , 2011). A natural goal is to carry out a marginal
analysis by estimating the rate of onset for each type of infection. However, the different
types of infections may arise due to the same underlying risk factors (e.g. a compromised
76
immune system due to malnutrition, exposure to contaminated areas, etc.). It can therefore
be informative to model the association between different types of infections.
Cai and Schaubel (2004) proposed semi-parametric marginal models for multi-type re-
current events data and develop robust standard errors. Chen and others (2012) developed
additive marginal models, proved the consistency of estimators, and derived their asymp-
totic distribution under a working independence assumption. Cook and others (2010)
proposed a copula-based bivariate mixed Poisson model with correlated random effects.
Mazroui and others (2013) also considered bivariate frailty models for two types of recurrent
events and death associated with two types of events based on maximum likelihood with
a piecewise baseline hazard function and maximum penalized likelihood. Also (Cook and
Lawless, 2007, Chapter 6) introduces different approaches in multitype recurrent events.
Even though the asymptotic theory is typically developed for multi-type recurrent event
data for the general setting, applications provided typically deal with only two types of
events. Frequentist methods based on flexible multivariate frailty models can be challenging
to implement with more than 2 event types, particularly when semiparametric methods
are of interest. We address this by developing a joint model for multiple types of recurrent
events using a multivariate random effects distribution constructed using a copula model to
link the component-specific random effects. This structure is appealing in that it enables
separate modeling of heterogeneity and dependence and offers a natural basis for use of
a composite “pairwise” likelihood approach to avoid the computational burden of the
full likelihood. We also investigate an even more computationally convenient two-stage
estimation procedure based on pairwise likelihood in which marginal models are fitted for
each type of event at the first stage, and the dependence parameters are estimated at the
second stage. Large sample theory is developed for both of these approaches.
The remainder of the Chapter is organized as follows. In the next sub-Section we
provide a brief review of composite likelihood. In Section 4.2 we introduce notation, pro-
vide details on the model formulation, and give the full and composite likelihoods. An
expectation-maximization algorithm is given in Section 4.3 for semiparametric analysis
based on multiplicative rate function models; variance estimation is given in an Appendix
4.A. Section 4.4 reports on simulation studies investigating the finite sample properties of
the simultaneous and two-stage estimation procedure based on pairwise composite likeli-
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hood and an application is given in Section 4.5 on a motivating study on the effect of iron
supplementation on the occurrence of different types of infections in malnourished children.
Concluding remarks are made in Section 4.6.
4.1.2 Review of Composite Likelihood
We let θ denote a p × 1 parameter of interest. In modeling multivariate data or in other
settings involving complex dependence structures, the full likelihood may be complex or
too computationally demanding to work with. As an alternative to full likelihood, Lindsay






a weighted product of marginal or conditional likelihood contributions Lj(θ; y); this may be
viewed as an as the extension of the concept of pseudo-likelihood (Besag, 1974). Each term
Lj(θ; y) is determined by the selection of {A1, . . . , AJ}, a set of marginal or conditional
events, where Lj(θ; y) ∝ f(y ∈ Aj; θ) (Varin and others , 2011). Varin (2008) provided the
excellent review of composite likelihood in different fields and classified composite likeli-
hood contributions as based on conditional or marginal likelihoods. Composite conditional
likelihoods are based on the product of conditional densities given conditions which the
analyst specifies, whereas the latter is constructed from marginal densities.
As in ordinary likelihood, the composite likelihood score equations are unbiased esti-
mating equations under mild regularity conditions. The maximum composite likelihood
estimator θ̂, obtained by solving the p× 1 equation
S(θ) = ∂ logCL(θ; y)/∂θ = 0,
is therefore consistent for θ. The robust covariance matrix has the form
G(θ) = A′(θ)B−1(θ)A(θ)
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where A(θ) = E(−∂S(θ)/dθ′) and B(θ) = E(S ′(θ)S(θ)) are p× p matrices and G(θ) is the
Godambe information matrix (Godambe, 1960).
4.2 Likelihood and Composite Likelihood Formula-
tion
4.2.1 Notation and Model Specification
Figure 4.1: Timeline diagrams for J different recurrent event processes and a common
censoring time
Suppose individuals are at risk of J types of events and let Tijk denote the time of the
kth occurrence type j event for an individual with label i. We let
dNij(s) = I(a type j event occurred at time s for individual i)
and let Nij(t) =
∫ t
0
dNij(s) record the cumulative number of type j events experienced by
individual i over (0, t]; the corresponding counting process is represented as {Nij(u), 0 < u}.
To consider all J events simultaneously we let dNi(s) = (dNi1(s), . . . , dNij(s))
′. A p × 1
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vector of fixed covariates, possibly unique for type j events, is denoted by xij and we let
xi = (x
′
i1, . . . , x
′
iJ)
′. The history for type j events is Hij(t) = {Nij(s), 0 ≤ s < t, xij} and
the full history of all types of events is Hi(t) = {Hi1(t), . . . , HiJ(t), 0 ≤ s < t}.
The complete intensity function for a type j event for individual i is
lim
∆t↓0
P (∆Nij(t) = 1|Hi(t))
∆t
= λij(t|Hi(t)),
j = 1, . . . , J , i = 1, . . . , n.
Suppose each individual in a sample of n independent individuals is to be followed
over (0, A] where A is an administrative censoring time. To accommodate possible early
study withdrawal, assumed to be conditionally independent of the event processes given
Xi, we define a random censoring time C
†
i for individual i and let Ci = min(C
†
i , A)
and Yi(s) = I(s ≤ Ci), i = 1, . . . , n. We then let dN̄ij(s) = Yi(s)dNij(s), dN̄i(s) =
(dN̄i1(s), . . . , dN̄iJ(s))
′, and N̄ij(t) =
∫ t
0
dN̄ij(s) which is the observed number of type j
events. We let H̄ij(t) = {N̄ij(s), Yi(s), 0 ≤ s < t, xij} and define the observed history
H̄i(t) = {H̄i1(t), . . . , H̄iJ(t), 0 ≤ s < t}.
In medical research, it is sometimes not possible to fully explain variation between
individuals simply by the incorporation of available covariates. To account for variation in
risk between individuals we consider a mixed Poisson model in which we introduce random
effects; this framework also allows for a dependence between event counts over disjoint
intervals (Lawless, 1987; Klein, 1992). We let Uij be a random effect for type j events for
individual i. Under a mixed Poisson model subject to independent right censoring, the
conditional intensity for observed type j events given the random effect Uij = uij is
lim
∆t↓0





where λj0(t;αj) denotes the baseline event rate function and the covariates have a multi-









We letGj(uij;σj) be the c.d.f. for Uij which are i.i.d. for all individuals, and consider the




To take into account the dependence between different types of events we consider the
joint density of U i = (Ui1, . . . , UiJ)
′ obtained using a Gaussian copula model (Nelsen,




dGj(uij;σj)c(G1(ui1;σ1), . . . , GJ(uiJ ;σJ); ρ)
where σ = (σ1, . . . , σJ)
′, Gj(uij;σj) is the marginal cumulative distribution function of Uij,
j = 1, . . . , J , and c(G1(ui1;σ1), . . . , GJ(uiJ ;σJ); ρ) can be written as


















where Φ−1(·) is the inverse cumulative distribution function of a standard normal and
R is a correlation matrix with (j, k) component ρjk explaining the association between




marginal parameters, and ψ = (ψ′1, . . . , ψ
′
J), and let φ = (σ
′, ρ′)′, and overall parameters
































4.3 Estimation Based on Composite Likelihood
4.3.1 Composite Likelihood Construction
In this setting, when the dimension of J increases, the inference of this model is computa-
tionally intractable as there is no closed-form for the full likelihood. We adopt composite
likelihood methods to resolve the computational difficulty in estimation. Thus instead of
maximizing the full log-likelihood (4.2.2), a pairwise log-likelihood is used for inference.
















dGjk(uij, uik;φjk) = dGj(uij;σj)dGk(uik;σk)c(Gj(uij;σ1), Gk(uik;σk); ρjk),
ηjk = (ψj, ψk, ρjk)
′, φjk = (σj, σk, ρjk)
′ andM is the collection of J(J − 1) pairs of (j, k) of
event types. We note that wjk = 1/(J−1) is chosen to make a single effective contribution
of each type of event for each individual to the composite likelihood.
4.3.2 A Semiparametric EM Algorithm for Estimation with Pair-
wise Likelihood
When margins are specified semiparametrically even solving (4.3.1) directly is difficult due
to the high dimension of the parameters. Here we adopt an expectation-maximization al-
gorithm in which we treat random effects as missing data and the data on the event process
as observed (Dempster and others , 1977). We specify, in this case, λj0(tjk) = dΛj0(tjk) as
an unspecified function and we estimate dΛj0(tjk) ≡ αjk and let θj = (dΛ′j0, β′j)′. Given
random effects we decompose the complete pairwise composite log-likelihood in (4.3.1) into
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logLij(θj|uij) + logLik(θk|uik) + log dGjk(uij, uik;φjk)
)
(4.3.2)
In the E-step, we take the conditional expectation of the complete pairwise composite
log-likelihood given the corresponding paired observed data. Here we define Hi,jk(t) =














where Ω̂(r−1) is an estimate of Ω at the (r− 1)st iteration. The estimating equation in the
















































uijP (Hi,jk(Ci)|uij, uik, xij, xik; θ̂(r)j , θ̂
(r)
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(r)














j (βj) = 0 in (4.3.4). The cumulative baseline rates are then estimated















The maximization of (4.3.3) in semi-parametric setting can be easily carried out using the
coxreg function in R with log((E[Uij|Hi,jk(Ci)] + E[Uik|Hi,jk(Ci)])/2) treated as an offset






wjkE[log dGjk(uij, uik;φjk)|Hi,jk(Ci), Ω̂(r−1)] (4.3.9)
using the standard optimization software such as the optim function in R. The E-step and
M-step are repeated iteratively until the following stopping rule is satisfied;
max(|Ω̂(r+1) − Ω̂(r)|) ≤ 10−4.
The variances of parameter estimates are obtained by the Godambe information matrix
(Godambe, 1960) which is written here as
Ĝ(Ω) = Â(Ω)′B̂(Ω)−1Â(Ω) (4.3.10)
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where logCL2i,jk = logLij(θj|uij) + logLik(θk|uik) + log dGjk(uij, uik;φjk). The details of
the variance estimation are presented in the Appendix 4.A. The calculation of conditional
expectation in (4.3.7), (4.3.9), (4.3.11), and (4.3.12) requires to use numerical integra-
tion. To facilitate shared-memory multi-processor, we implement OpenMP (Open Multi-
Processing) interface in C++ to obtain numerical integration by Gaussian-Quadrature with
20 nodes for each dimension.
4.3.3 Two-stage Semiparametric Estimation with Pairwise Like-
lihood
The implementation of a two-stage estimation procedure can ease computation (Zhao and
Joe, 2005; Andersen, 2004). In the first stage, the parameters for each type of event,
ψj = (θj, σj)
′, are estimated under a working independence assumption. We also use the
expectation-maximization algorithm treating a random effect for each type as missing data
to obtain ψ̂j. Given a random effect uij, the complete likelihood function for each type is

















j (s; βj) in (4.3.6) becomes
R
(h,r)
j (s; βj) =
n∑
i=1
Ȳi(s)E[Uij|Hij(Ci), ψ̂(r)j ] exp(x′ijβj)xhij. (4.3.14)
We calculate E[Uij|Hij(Ci); ψ̂(r)j ] as
E[Uij|Hij(Ci); ψ̂(r)j ] =
∫∞
0




P (Hij(Ci)|uij, xij; θ̂(r)j )dGj(uij; σ̂
(r)
j )














The procedure is iterated until convergence. In the second stage, we solve the composite
score function from the pairwise likelihood with respect to ρ plugging the estimates ψ̂ from
the stage 1. Again, we implement the expectation-maximization algorithm with random
effects treated as missing data in which we obtain the dependence parameter by maximizing





wjkE[log dGjk(uij, uik;σj, σk, ρjk)|Hi,jk(Ci), ρ̂(r−1), ψ̂j, ψ̂k].
Zhao and Joe (2005) commented that two-stage estimation in composite likelihood is rec-
ommended with a weak dependence. In a strong dependence case, the simultaneous esti-
mation method gives better estimates. The variance estimates in two-stage estimation are
present in Appendix 4.A. The code is available from the author upon request.
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4.4 Simulation Studies
Simulation studies were conducted to evaluate the performance of estimators from the joint
models introduced in Section 4.2. We consider three different types of infections (J=3). For
a randomized treatment, we let xi the indicator of treatment where xi = 1 having treatment
otherwise xi = 0 where P (Xi = 1) = 0.5. We generate the data over the interval (0, 1] with
an independent random censoring Ci. We assume that Ci follows an exponential distribu-
tion with rate − log(0.9) indicating 10% censoring. The marginal rate functions are of the
form αλtα−1 exp(−λtα). We set (λ1, α1) = (1, 1), (λ2, α2) = (1.5, 1.25), (λ3, α3) = (2, 1.25)
and the coefficients β1 = β2 = β3 = log(0.8). We consider the Gaussian copula with
log-normal margins for random effects where E(Uij) = 1 and Var(log(Uij)) = σ
2
j . We
set the frailty parameters as σ1 = 0.4, σ2 = 0.4, σ3 = 0.4, and the association param-
eters as (ρ12, ρ13, ρ23) = (0.25, 0.25, 0.25), and (ρ12, ρ13, ρ23) = (−0.25,−0.25, 0.25). We
generated 500 samples of 1000 individuals. For each data set, parametric and semi-
parametric analyses are carried out based on the pairwise likelihood likelihoods in Sec-
tion 4.3.2, and two-stage estimation based on the pairwise likelihood in Section 4.3.3.
For models with parametric baseline rate functions such as Weibull model, the marginal
parameters θj = (λj, αj, βj)




αj−1 using standard optimization software such as the optim function in
R. The empirical bias (EBIAS), average asymptotic (large sample) standard error (ASE),
empirical standard error (ESE) and empirical coverage probability (ECP) are evaluated
for all parameter estimates and reported in Table 4.1 and 4.2.
The empirical biases are very small for all estimates of parameters and empirical stan-
dard errors and average estimated standard errors are in good agreement. The empirical
coverage probability are close to the nominal confidence level of 95%. Comparing para-
metric and semi-parametric model, we find that all estimates and standard errors are very
close between two models. However, to protect from the model misspecification, semi-
parametric model is recommended although the computation is intense compared to the
parametric model. The standard errors of estimators of marginal parameters are very close
between the pairwise simultaneous and two-stage model whereas there is some efficiency
gain in dependence parameters with the simultaneous model compared to the two-stage
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Table 4.1: Frequency properties of estimators obtained by fitting a Weibull-model using
the pairwise likelihood and two-stage estimation based on the pairwise likelihood with the
sample size 1000 and nsim = 500; (ρ12, ρ13, ρ23) = (0.25, 0.25, 0.25)
Pairwise Likelihood Two-stage Pairwise Likelihood
TYPE PARAM EBIAS ESE ASE ECP EBIAS ESE ASE ECP
Weibull Model
1
λ1 0.000 0.050 0.050 0.952 -0.001 0.050 0.050 0.950
α1 0.000 0.035 0.034 0.944 0.001 0.035 0.034 0.942
β1 -0.003 0.072 0.074 0.958 -0.002 0.072 0.074 0.958
σ1 -0.002 0.064 0.069 0.962 -0.003 0.064 0.070 0.968
2
λ2 -0.006 0.062 0.063 0.944 -0.007 0.061 0.063 0.950
α2 0.000 0.035 0.035 0.948 0.001 0.036 0.035 0.948
β2 0.003 0.060 0.062 0.958 0.004 0.060 0.063 0.958
σ2 -0.003 0.048 0.051 0.970 -0.002 0.048 0.051 0.974
3
λ3 -0.007 0.078 0.075 0.934 -0.006 0.077 0.075 0.938
α3 0.001 0.031 0.030 0.944 0.001 0.031 0.030 0.942
β3 0.005 0.054 0.056 0.956 0.004 0.053 0.056 0.962
σ3 -0.003 0.040 0.041 0.960 -0.003 0.040 0.041 0.966
Copula
ρ12 -0.012 0.213 0.234 0.966 -0.008 0.220 0.235 0.960
ρ13 0.003 0.189 0.207 0.962 0.009 0.194 0.208 0.960
ρ23 0.007 0.168 0.172 0.956 0.010 0.168 0.172 0.958
Semiparametric Model
1
Λ1(1) 0.000 0.051 0.050 0.934 -0.001 0.051 0.050 0.934
β1 -0.005 0.073 0.074 0.946 -0.006 0.073 0.074 0.946
σ1 -0.006 0.062 0.069 0.964 -0.007 0.062 0.070 0.972
2
Λ2(1) 0.003 0.061 0.063 0.952 0.003 0.061 0.063 0.950
β2 -0.003 0.061 0.062 0.948 -0.003 0.061 0.062 0.948
σ2 -0.007 0.052 0.051 0.950 -0.005 0.052 0.051 0.954
3
Λ3(1) 0.002 0.082 0.075 0.914 0.002 0.082 0.075 0.912
β3 -0.004 0.055 0.056 0.954 -0.004 0.055 0.056 0.956
σ3 -0.005 0.039 0.041 0.974 -0.005 0.039 0.041 0.970
Copula
ρ12 -0.010 0.221 0.239 0.964 -0.005 0.226 0.240 0.960
ρ13 0.009 0.193 0.210 0.966 0.013 0.197 0.212 0.968
ρ23 0.016 0.171 0.175 0.964 0.017 0.174 0.175 0.958
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Table 4.2: Frequency properties of estimators obtained by fitting a Weibull-model using
the pairwise likelihood and two-stage estimation based on the pairwise likelihood with the
sample size 1000 and nsim = 500; (ρ12, ρ13, ρ23) = (−0.25,−0.25, 0.25)
Pairwise Likelihood Two-stage Pairwise Likelihood
TYPE PARAM EBIAS ESE ASE ECP EBIAS ESE ASE ECP
Weibull Model
1
λ1 -0.001 0.053 0.049 0.940 -0.001 0.053 0.049 0.940
α1 0.002 0.035 0.034 0.950 0.002 0.034 0.034 0.950
β1 -0.005 0.073 0.074 0.954 -0.005 0.073 0.074 0.954
σ1 -0.009 0.061 0.069 0.966 -0.011 0.062 0.071 0.972
2
λ2 0.002 0.063 0.063 0.952 0.002 0.063 0.063 0.954
α2 0.001 0.033 0.035 0.952 0.001 0.034 0.035 0.952
β2 -0.003 0.062 0.062 0.938 -0.003 0.062 0.062 0.938
σ2 -0.006 0.050 0.050 0.958 -0.006 0.051 0.051 0.962
3
λ3 0.000 0.078 0.075 0.938 0.000 0.078 0.075 0.936
α3 0.002 0.029 0.030 0.946 0.001 0.029 0.030 0.946
β3 -0.002 0.056 0.056 0.948 -0.002 0.056 0.056 0.950
σ3 -0.005 0.040 0.041 0.942 -0.006 0.040 0.041 0.946
Copula
ρ12 -0.011 0.214 0.244 0.980 -0.018 0.219 0.248 0.980
ρ13 0.007 0.203 0.216 0.964 0.002 0.209 0.232 0.964
ρ23 -0.011 0.169 0.174 0.958 -0.010 0.170 0.174 0.956
Semiparametric Model
Type1
Λ1(1) -0.001 0.053 0.049 0.940 -0.001 0.053 0.049 0.938
β1 -0.005 0.073 0.074 0.956 0.002 0.073 0.074 0.954
σ1 -0.009 0.062 0.069 0.960 -0.011 0.062 0.071 0.972
Type2
Λ2(1) 0.002 0.063 0.065 0.956 0.002 0.063 0.063 0.952
β2 -0.004 0.062 0.062 0.936 -0.003 0.062 0.062 0.936
σ2 -0.006 0.050 0.053 0.952 -0.006 0.050 0.051 0.962
Type3
Λ3(1) 0.001 0.078 0.077 0.936 0.000 0.078 0.075 0.936
β3 -0.002 0.056 0.056 0.950 -0.002 0.056 0.056 0.948
σ3 -0.005 0.041 0.042 0.938 -0.005 0.040 0.041 0.946
Copula
ρ12 -0.012 0.213 0.245 0.970 -0.018 0.219 0.248 0.980
ρ13 0.008 0.203 0.217 0.936 0.002 0.209 0.230 0.966
ρ23 -0.011 0.169 0.174 0.936 -0.010 0.170 0.174 0.956
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model. In this simulation studies, we only consider three types of events in which pair-wise
likelihood approach is feasible. However, if more than three events are analyzed two-stage
methods are plausible.
4.5 Recurrent Infections in a Pediatric Trial of Iron
Supplementation
Lemaire and others (2011) conducted a randomized clinical trial of 268 Bangladeshi mal-
nourished children, aged 12-24 month in which children were randomly given iron-containing
micro-nutrient powder (iron MNP) or a placebo powder as mentioned in Section 1.3.3.
Given this data, interest lies on how to examine the effect of treatment on the incidence of
multiple diseases which are caused by malnutrition and iron deficiency. An analysis based
on a composite score is feasible (Lemaire and others , 2011), however it leads to losing in-
formation on distinct episodes. Often interest lies in a treatment effect on specific disease,
however, since the lack of nutrition directly or indirectly affects the immune system, the
different types of infections in consequence of malnutrition may be associated. Therefore
somewhat related diseases should be considered together.
Figure 4.2: Diarrhea, dysentery event plots for phase 1 and phase 2 showing the onset and
the duration of episodes
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Table 4.3: Joint analysis of three types of infections based on semiparametric model;
diarrhea, dysentery and cough with covariates iron and phase
Semiparametric Pairwise Likelihood Two-stage PW Likelihood
TYPE Covariate EST SE p EST SE p
Coefficients
Diarrhea
Iron -0.265 0.140 0.058 -0.265 0.140 0.058
Phase 0.310 0.138 0.025 0.310 0.138 0.025
Dysentery
Iron 0.200 0.244 0.412 0.202 0.244 0.407
Phase 0.562 0.248 0.023 0.564 0.246 0.022
Cough
Iron -0.163 0.108 0.131 -0.163 0.108 0.131
Phase 0.380 0.109 < 0.001 0.380 0.109 < 0.001
Random effects
(σ1, σ2, σ3) (0.405, 0.530, 0.314) (0.372, 0.526, 0.313)
(0.094) (0.117) (0.092) (0.120) (0.218) (0.089)
Dependence Parameters
(ρ12, ρ13, ρ23) 0.906 -0.250 -0.379 0.885 -0.276 -0.379
(0.211) (0.492) (0.617) (0.196) (0.529) (0.609)
Figure 4.2 displays diarrhea and dysentery data for each individual with two-phase
where lines represent a period of diseases. The onset of diarrhea and dysentery may be
correlated, which should be taken into account for an analysis of this data. In our analysis,
we select three types of events; diarrhea, dysentery, and cough. Since Figure 4.2 shows
that different phase may influence the occurrence of infections we first consider the iron
supplement and iron as covariates. We conduct full likelihood and pairwise likelihood in
application since the number of subjects is only 268 so that full likelihood is also feasible.
The results using the proposed methods are summarized in Table 4.3. We observe
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the iron supplements do not have significant effects on the occurrence of all three types of
events. The iron supplements reduce the occurrence of diarrhea (RR : 0.77; 95% CI: (-0.54,
0.01), p = 0.058 with pairwise likelihood) and cough (RR : 0.85; 95% CI: (-0.38, 0.05),
p = 0.131 with pairwise likelihood) whereas it increases the onset of dysentery (RR : 1.22;
95% CI: (-0.28, 0.68), p = 0.412 with pairwise likelihood). We note that the change of
phase from 1 to 2 significantly increases the occurrence of all type of events; phase 2 repre-
sents the winter period so that viral diarrhea increases onset of diarrhea (RR : 1.36; 95%
CI: (0.04, 0.58), p = 0.025 with pairwise likelihood) and dysentery (RR : 1.75; 95% CI:
(0.08, 1.05), p = 0.023 with pairwise likelihood). Also the onset of cough may increases due
to seasonal factors (RR : 1.46; 95% CI: (0.16, 0.60), p < 0.001 with pairwise likelihood).
All three types of infections show heterogeneity where σ̂1 = 0.41, σ̂2 = 0.53, σ̂3 = 0.31 with
pairwise likelihood. From the estimates of dependence parameters, diarrhea infection have
a strong positive association with both diarrhea infections (ρ̂12 = 0.91 with pairwise like-
lihood). There are negative associations between gastrointestinal infections (diarrhea and
dysentery) and cough (ρ̂13 = −0.26, ρ̂23 = −0.38 with pairwise likelihood). If the depen-
dence parameter is close to 1, it may be better to combine two events since the underlying
mechanism of two events may be identical. We note that the estimates of covariate effects
based on pairwise likelihood and two-stage pairwise likelihood are almost identical, which
indicates that marginal covariate effects are robust to dependence parameter.
Figure 4.3 shows the expected number of each episode under the pairwise likelihood
for phase 1 and 2, respectively. The infection of diarrhea and cough for the placebo group
have approximately 1 event occurrence for the period 12/2007-06/2008 (phase 1) and the
iron supplement group has lower expected number of episodes. The expected number of
events of dysentery for the placebo group is approximately 0.2 which has low incidence
compared to the onset of diarrhea.
4.6 Discussion
We propose the use of a multivariate random effects distribution to model heterogeneity in
the risk of several types of recurrent events based on a mixed Poisson model formulation.
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Figure 4.3: Plots of estimated expected number of diarrhea, dysentery, and cough events
for placebo and iron MNP group with two phase for the pairwise likelihood analysis using
the joint model
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The joint distribution of the random effects is constructed via a Gaussian copula model
which means that the measures of overdispersion for each type of event are functionally
independent and that the dependence structure is quite general. Semiparametric estimation
is carried out using a composite likelihood expectation-maximization algorithm; an even
more computationally efficient two-stage estimation procedure is also developed which
simply uses a working independence assumption at the first stage. Large sample variance
estimates are derived for both approaches and are shown to be valid in finite samples in
empirical studies. The approach is particularly appealing for use in settings with many
different types of events. From intermittent inspection, interval-censoring naturally arises
in longitudinal data. We can extend our methods to incorporate this feature of data.
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Appendix 4.A: Calculation of the Variance Estimates
1. Expressions for Simultaneous Estimation
To obtain the estimates of covariance matrix in (4.3.10), we need to calculate Â and B̂ in
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3. The Conditional Score Vector and the Conditional Information
Matrix
The conditional score vector ∂Lij(θj|uij)/∂θj for βj, dΛj0(·) in the complete pairwise like-


























where tjk is the k
th time of type j event occurrence.
































In (4.3.2), log dG(uij, uik;φjk) is given as




























































The components of the conditional score vector ∂ log dG(uij, uik;φjk)/∂φjk are given as
follows.















































































































The elements of the conditional information matrix −∂2 log dG(uij, uik;φjk)/∂φjk∂φ′jk
are as follows.
−∂



































































































































































































The conditional score function and the conditional information function for σj from


























The Illness-Death Model for Family
Studies
5.1 Introduction
Family studies are conducted to assess the nature and extent of familial aggregation of
disease, as well as the effect of genetic factors on disease onset. When present, familial
aggregation suggests a shared genetic or environmental basis of disease (Li and others ,
1998; Liang and Beaty, 2000). For valid inference in such settings, however, it is important
to address the sampling scheme by which family members are recruited. Typically an
individual with the disease, called the proband, is recruited to the study and provides a
detailed disease history including the age of disease onset. The disease onset time for this
individual is right-truncated since they had to be affected to be sampled, but their survival
time is left-truncated. The family members of the proband, called non-probands, are then
selected for the family study. In some settings the proband may report the disease history
of their family members, but it may alternatively be acquired through clinical examination
conducted by a physician.
A variety of methods for the analysis of multivariate failure time data methods have
been developed (Hougaard, 2000). A non-parametric estimate was suggested by Dabrowska
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(1988). Wei and others (1989) introduced marginal models for different types of failure and
developed methods for the robust estimation of standard errors. The marginal apporach for
the analysis of clustered failure time data has been developed in general by Lee and others
(1992) and by Liang and others (1993) for family studies. Clayton (1978) suggested use of
the cross-ratio as a dependence measure, and Oakes (1989) showed the connection between
frailty models and the cross-ratio hazard function. Frailty models have been widely used in
the analysis of case-control family studies (Hsu and others , 2004; Hsu and Gorfine, 2005)
where a frailty variance is interpreted as a measure of dependence in the age of onset within
family members. Copula models can alternatively be used, in which case the multivariate
joint distribution is formulated in terms of the marginal distributions and a copula function
(Joe, 1997; Shih and Louis, 1995). Li and others (1998), Shih and Chatterjee (2002), and
Chatterjee and others (2006) developed the copula models for case-control family studies
considering the ascertainment of case-control probands. Zhong and Cook (2016) used
copula functions and composite likelihood for the analysis of right-censored and current
status family data while addressing complex sampling schemes. Zhong and Cook (2017)
developed estimating function methods and considered the implications of different forms
of the estimating functions in terms of robustness and efficiency.
The aforementioned methods focus on modeling familial aggregation in disease onset
times in the simple framework of time to event data. More recent work has dealt with
clustered failure time data in the semi-competing risks setting, where disease onset and
disease-free death are considered as competing events. Bandeen-Roche and Liang (2002)
suggested a modified conditional hazard ratio to account for the cause of failure based on
a frailty model and applied it to a population cohort study of dementia. Shih and Albert
(2010) extended the work of Bandeen-Roche and Liang (2002) and considered two types
of dependence measures with one to model the dependence in terms of the failure time of
paired members and a second to model the association between the failure types given the
time; they suggested use of a time-varying piecewise constant dependence measure. To
examine sibship association in disease onset, Cheng and others (2009) developed nonpara-
metric association analysis using the bivariate cumulative incidence function defined by the
cause-specific hazard function to account for the exchangeable clustered competing risks
setting. Zhou and others (2012) proposed a marginal proportional subdistribution hazard
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model in the clustered competing risks setting. Scheike and others (2010) and Scheike
and Sun (2012) studied a semiparametric additive model and explored a cross-odds ratio-
type measure on the probability scale as the association parameters for the Danish twin
data; Scheike and others (2014) extended the model to accommodate delayed entry and to
accommodate genetic and environmental effects.
Multi-state models offer another framework for dependence modeling. Aalen and others
(1980) applied the Schweder (1970) concept of local dependence to understand the inter-
action between two life history events by comparing the transition intensities. Hougaard
and others (1992) and Hougaard (1999) considered dependence modeling in the life times
of twins via multistate models under the Markov or semi-Markov assumption.
There has been little work on the use of illness-death models in the setting of family
or twin studies. The illness-death model is a useful framework for event history analysis
when not only disease incidence but also mortality is considered for better understanding of
the life history process (Andersen, 1988). Dependence modeling of correlated illness-death
processes is necessary when data are clustered as in family studies. (Cook and Lawless,
2018, Section 6.2) discuss a variety of methods for dependence modeling for clustered or
otherwise correlated multistate processes. Some of these apply generally while much of the
discussions invlovles progressive process. Jiang and Haneuse (2017) proposed an illness-
death model with a non-parametric frailty distribution where the non-terminal event times
and terminal event times are correlated.
In this chapter, we develop an illness-death model using the latent variable formulation
of the competing risk model for the first event (disease onset or disease-free death). A cop-
ula model is used to accommodate clustering in the ages of disease onset within families.
Methods are described which account for incomplete data under two types of biased sam-
pling schemes. The use of auxiliary data is highlighted to address identifiability problems
and to increase the efficiency. Finally, we show how to account for incomplete genetic data
when auxiliary data do not have genotype information available.
The remainder of this contribution is organized as follows. In Section 5.2 we define no-
tation and present the joint model. Two study designs under the biased sampling schemes
are then described and the associated likelihood is presented; composite likelihood is pro-
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posed for settings where some family sizes are large. The use of auxiliary data is discussed
in Section 5.3 to facilitate estimation of transition intensities to the death state, and simu-
lation studies are reported in Section 5.4. In Section 5.5, we extend the proposed methods
to incorporate genotype information and present the results of further simulation stud-
ies. An application to a family study on the onset of psoriatic arthritis (PsA) from the
University of Toronto is given in Section 5.6 and concluding remarks are given in Section
5.7. Remarks on computational methods are given in Appendix 5.A and the method for
modeling missing genetic data is described brifely in Appendix 5.B
5.2 Model Formulation
5.2.1 Notation and Model Formulation
We consider a four-state model illness-death model to describe the joint distribution of
disease onset and death (Datta and others , 2000; Xu and others , 2010). We let state
0 represent a healthy state, state 1 represent a diseased state, state 2 represent death
post-disease, and state 3 represent disease-free death; see Figure 5.1. Our initial interest
lies in modeling the dependence between family members in the age of disease onset. To
discuss the joint model in the greatest simplicity, we first consider dependence modeling
for individuals labeled j and k in family i, and define variables for individual j without loss
of generality. We let Xij1 denote the age of disease onset, Xij2 the age at death following
disease, Xij3 the age at disease-free death. Note that this is a latent variable formulation
of the semi-competing risks problem for transition out of state 0 in that Xij1 may not be
observed (or realized) if Xij3 < Xij1. While unconventional and not without limitations in
terms of its connection with observable features, we adopt this formulation here since the
association in the age of disease onset is most naturally modeled in terms of the 0 → 1
transition times. Finally we let Bij be the calendar time of birth for individual j in family
i, j = 1, 2, and let Bi = (Bij, Bik)
′ be the vector of calendar times of births for individuals
j and k in family i.
It is also helpful to use notation for multistate models and so we let Zij(a) denote the












Figure 5.1: A four-state representation of an illness-death model
where nF is the number of families recruited. We let Vij denote covariates for individual
j in family i and V i = (Vij, Vik)
′. Let Hij(a) = {Zij(s), 0 ≤ s < a,Bij, Vij} denote the
history for individual j in family i over age [0, a) whose calendar time of birth is Bij. The





−) = l|Zij(a−) = h,Hij(a))
∆a
= λijl(t, a|Hij(a))
with t = Bij + a where (h, l) ∈ {(0, 1), (0, 3), (1, 2)}. If the disease process for each family
member is Markov given the date of birth and the covariates, we can write
λij(t, a|Hij(a)) = λl(t, a|bij, vij), l = 1, 2, 3.
If we assume that λ3(t, a|bij, vij) = λ2(t, a|bij, vij), the disease is incidental in that it does
not change the risk of death, but if λ3(t, a|bij, vij) 6= λ2(t, a|bij, vij), then survival is locally
dependent of the disease process (Aalen, 2012); in this case, typically, λ2(t, a|bij, vij) >
λ3(t, a|bij, vij). Andersen and others (1985) use a Cox model to accommodate proportional
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mortality among diseased and disease-free individuals. In the present context, this has the
form
λ2(t, a|bij, vij) = λ3(t, a|bij)ν0(a) exp(v′ijβ2), (5.2.1)
where λ3(t, a|bij) is the age- and calendar-time specific baseline population mortality rate.
The term ν0(a) reflects a proportional change in mortality in terms of age. We adopt the
model (5.2.1) and let λ3(t, a|bij, vij) = λ3(t, a|bij) so that the subject-specific disease-free
mortality rate does not depend on the covariates and can be therefore easily estimated
based on the population rates. If the disease does not alter the mortality trend in age in
the population, we may assume ν0(a) = ν.
Here, the transition times Xij1 and Xij3 are defined to be statistically independent,
and we note that we only observe min(Xij1, Xij3) (Kalbfleisch and Prentice, 2011). For
transitions from the healthy to diseased state, we assume that the intensity does not depend
only on calendar time, in which case we may write λ1(t, a|bij, vij) = λ1(a) exp(v′ijβ1). Under
the assumption of independent competing risks, we denote the survival functions for the
latent disease onset time as F(a|Vij;φ1) = 1−exp(−
∫ a
0
λ1(a|Vij)da), and let f(a|Vij;φ1) =
−∂F(a|Vij;φ1)/∂a where φ1 indexes the marginal intensity for disease onset. To identify
the nature of familial aggregation in the age of disease onset, we construct a joint model
for Xij1 and Xik1 using a copula function (Joe, 1997) in which
P (Xij1 > aj, Xik1 > ak;V i, ϕ) = C(F(aj|Vij;φ1),F(ak|Vik;φ1); ρ), (5.2.2)
where ρ indexes the copula function and ϕ = (φ′1, ρ)




indexes the transition intensity from the diseased to death state and ψ = (φ′, ρ). The joint
density function can be written as
P (Xij1 = aj, Xik1 = ak;V i, ϕ) =c(F(aj|Vij;φ1),F(ak|Vik;φ1); ρ)f(aj|Vij;φ1)f(ak|Vik;φ1),
where c(·, ·; ρ) is the density of the copula. We here consider the Clayton copula which has
the form
C(u1, u2; ρ) = (u−ρ1 + u
−ρ
2 − 1)−1/ρ
with Kendall’s τ = ρ/(ρ + 2). Mesfioui and Quessy (2008) showed that the conditional
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Clayton copula has an invariance property; in the present context, if Xi1 = (Xij1, Xik1, Xil1)
follows a joint distribution with a dependence model governed by the Clayton copula,
then the distribution of Xij1, Xik1|Xil1 = xil1 follows the Clayton copula with parameter
ρ/(1 + ρ), so,
P (Xij1 > aj, Xik1 > ak|Xil1 = al, Vij, Vik, Vil) (5.2.3)
= C(F(aj|Xil1 = al, Vij, Vil;φ1, ρ),F(ak|Xil1 = al, Vik, Vil;φ1, ρ); ρ∗),
where ρ∗ = ρ/(1 + ρ) and






As a measure of dependence of the age of disease onset between two individuals, we
consider the cross ratio for (Xij1, Xik1) (Oakes, 1989) which takes the form of
θ(aj, ak) =
λ1(ak|Xij1 = aj;V i, ϕ)
λ1(ak|Xij1 > aj;V i, ϕ)
(5.2.4)
=
P (Xij1 = aj, Xik1 = ak;V i, ϕ)P (Xij1 > aj, Xik1 > ak;V i, ϕ)
P (Xij1 = aj, Xik1 > ak;V i, ϕ)P (Xij1 > aj, Xik1 = ak;V i, ϕ)
.
We note that under the Clayton copula, θ(aj, ak) = 1 + ρ. We assume that the (possibly
latent) age at disease-free death for an individual is independent from the life history of
other family members. This assumption may not be valid in settings where the occurrence
of death might be affected by shared environmental factors in a family. Nevertheless we
adopt it here, recognizing that there is a within-family dependence in the marginal time of
death (min(Xij2, Xij3)) accommodated. Note that under the assumption of i) conditionally
independent competing risks, Xij1 ⊥ Xij3|Vij, and ii) Xij3 ⊥ {Zik(s), 0 < s}|Bi,V i for
j 6= k, a cause-specific cross-ratio θ11(aj, ak) for the age of disease onset between two
individuals is the same as the cross odds ratio θ(aj, ak) in (5.2.4). This is true since




λ11(ak|Xij1 = aj, Xij3 > aj;Bi,V i, ϕ)
λ11(ak|Xij1 > aj, Xij3 > aj;Bi,V i, ϕ)
=
λ1(ak|Xij1 = aj;V i, ϕ)
λ1(ak|Xij1 > aj;V i, ϕ)
,
where θ11(·) represents the cause-specific hazard ratio for the transition from 0 to 1 for
two members, λ1(ak|Xij1 = aj, Xij3 > aj;Bi,V i, ϕ) is the conditional hazard at disease
age ak given the other family member has disease at age aj, and λ1(ak|Xij1 > aj, Xij3 >
aj;Bi,V i, ϕ) is the conditional hazard at disease age ak given the other family member is
in healthy state at age aj under the semi-competing risks setting. Here, we consider the
Clayton copula and we let θ(aj, ak) = θ11(aj, ak) = θ = 1 + ρ. Note that since the age
of disease onset between family members are correlated, Xij2 may not be independent of
Xik2.
Scheike and others (2010) introduced a cross-odds ratio for the age of disease onset
under the competing risks setting given by
π(a) =
ODDS(Xik1 ≤ a,Xik1 < Xik3|Xij1 ≤ a,Xij1 < Xij3;Bi,V i)
ODDS(Xik1 ≤ a,Xik1 < Xik3, Bik, Vik)
,
where
P (Xik1 ≤ a,Xik1 < Xik3, Bik, Vik) (5.2.5)
is the marginal cumulative incidence function for the age of disease onset. Note that
π(a) does not have a simple expression even with θ(a, a) = 1 + ρ under the Clayton cop-
ula, because the cumulative incidence functions are obtained by the cause-specific hazards
λ1(·), λ2(·), and λ3(·).
5.2.2 Likelihood Construction for Family Studies
We now extend the model to deal with all members of a family. We let mi + 1 denote
the total number of members of family i with the subscript 0 used to denote the proband
in the family. Let X i1 = (Xi01, Xi11, . . . , Ximi1)
′ denote the vector of possibly latent
onset times within family i, X i3 = (Xi03, Xi13, . . . , Ximi3)
′,X i2 = (Xi02, Xi12, . . . , Ximi2)
′,
Bi = (Bi0, . . . , Bimi)
′, and V i = (Vi0, . . . , Vimi)
′. Then (5.2.2) extends tomi+1 dimensional
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survival copula function as
P (Xi01 > a0, . . . , Ximi1 > ami |V i;ϕ) = C(F(a0|Vi0;φ1), . . . ,F(ami |Vimi ;φ1); ρ).
We consider studies in which families are sampled by the selection of the proband from
a disease registry. We label the proband j = 0 and selected family members by j =
1, . . . ,mi, i = 1, . . . , nF . We let Ri0 denote the calendar time of screening and recruitment
of the proband to the registry and Ci0 = Ri0−Bi0 the age of the proband at calendar time
Ri0. To be in the registry, the proband must be alive with disease at age Ci0. Let Ri be the
calendar time of the second stage of sampling of the proband from the registry for inclusion
in the family study, and Ai0, and Ai = (Ai0, Ai1, . . . , Aimi)
′ denote the age at calendar time
Ri for the proband and all family members, respectively; let A
−
i = (Ai1, . . . , Aimi)
′ denote
the elements of Ai excluding the proband. More generally a superscript “-” denotes a
vector with the entry for the proband excluded.
Given the life history of the proband, we obtain data from the non-probands. If a non-
proband died before Ri, it is often possible to obtain disease history data from medical
records or via the proband. Anderson (1961) compared the accuracy of reports about
disease histories of family members with diagnosis data from physicians, and found that
obtaining information from physicians is necessary to ensure accurate reporting is made for
non-probands. We therefore also consider designs in which physicians must interview non-
probands at calendar time Ri to carry out medical examinations. In this second design,
non-probands would have to be alive at the family recruitment time Ri.
The Lexis diagram plays a central role in describing the incidence, path, and sampling of
disease processes in a population using a calendar time × age co-ordinate system (Keiding,
1990, 2006). Figure 5.2 shows possible scenarios for family data on illness-death processes
under the biased sampling scheme. In this figure, the dashed lines represent periods of
calendar time and ages at which the healthy state is occupied, and the solid lines represent
periods in which the diseased state is occupied. The proband, depicted in red, provides
their retrospectively recorded age of disease onset, and like other individuals in the registry
may be followed until death or censoring. Non-probands may give a mixed type of data.
Some may give retrospectively reported ages of disease onset, some may be disease-free at
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the time of examination, and for some we may simply know their date of death if they
did not live long enough to be recruited and examined at the calendar time of the family
study.
Figure 5.2: A Lexis diagram for family data obtained under a biased sample scheme; Ri0
denotes the calendar time of recruitment of a proband to a registry and Ri is the date of
the family study.
We construct the likelihood function for two particular study designs under the biased
sampling schemes, depending on whether we collect all history of non-probands at Ri or
only examine non-probands who are alive at Ri. If si = (si0, si1, . . . , simi)
′ denotes a vector
of ages of individuals in family i, we let Zi(si) = (Zi0(si0), Zi1(si1), . . . , Zimi(simi))
′. In
both designs the likelihood contribution of the proband is
Li0(φ) = P (Z̄i0(Ai0)|Zi0(Ci0) = 1, Ci0, Bi0, Vi0;φ), (5.2.6)
where Z̄i0(Ai0) = {Zi0(u), 0 < u ≤ Ai0}. In the first design we suppose the disease history
and covariates for all non-probands are available at calendar time Ri at which the family
study is conducted. The likelihood is then given as




i )|Z̄i0(Ai0), Zi0(Ai0) = 1,Ai,Bi,V i;ψ), (5.2.7)
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where Z̄i(si) = {Zij(u), 0 < u ≤ sij, j = 0, . . . ,mi} and Z̄ij(s) = {Zij(u), 0 < u ≤ s}.
In the second design we consider a study in which non-probands must be alive to be
examined and participate in the family study. This gives




i )|Z̄i0(Ai0), Zi0(Ai0) = 1,Z−i (A−i ) ∈ {0, 1}mi ,Ai,Bi,V i;ψ).
(5.2.8)
In what follows we omit the superscript I and II indicating the design and take it as




















respectively. We obtain the maximum likelihood estimator ψ̂ by solving S(ψ) = 0 and
asymptotically
√
nF (ψ̂ − ψ) ∼ N(0, I−1(ψ)) where I(ψ) = E[Ii(ψ)].
When mi is large the computational burden of evaluating the joint probability of the
life histories of family members may be considerable, so we consider use of “pairwise” con-
ditional composite likelihood (Varin and others , 2011) in which pairs are comprised of two
non-probands and the models condition on the proband data for this respective family. In
particular, in the second design in (5.2.8) where non-probands are only selected if they are
alive, the composite likelihood is exploited to address the difficulty of calculating the con-




i ) ∈ {0, 1}mi ,Ai,Bi,V i). Then, the contribution
to the conditional composite likelihood of family i for design k is








k = I, II, (5.2.9)
where Li0 is given by (5.2.6); the weight 1/(mi−1) ensures the contribution to the marginal
function for non-probands is appropriate. In design I,




ijl)|Z̄i0(Ai0), Zi0(Ai0) = 1,Aijl,Bijl,V ijl;ψ)
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and in design II,















ijl)|Z̄i0(Ai0), Zi0(Ai0) = 1,Aijl,Bijl,V ijl;ψ)
P (Z−ijl(A
−
ijl) ∈ {0, 1}2|Z̄i0(Ai0), Zi0(Ai0) = 1,Aijl,Bijl,V ijl;ψ)
with Aijl = (Ai0, Aij, Ail)
′,Bijl = (Bi0, Bij, Bil)







′, Z̄ijl(sijl) = {Zih(u), 0 <
u ≤ sih, h = 0, j, l;Bijl}. We calculate Lkijl(ψ) using the conditional Clayton copula func-
tion based on (5.2.3). The detail of computation of composite likelihood is given in Ap-
pendix 5.A. Again we suppress the superscript I or II when discussing a generic setting we






∂ logCLi(ψ)/∂ψ = and the maximum composite likelihood estimator ψ̃ is obtained by












5.3 Augmented Composite likelihood
In the context of family study, the low incidence of disease onset among non-probands and
bias sampling scheme pose difficulty for analysis due to the lack of data. To overcome this
difficulty, auxiliary data can provide additional source of data and strengthen the analysis.
The combination of data from different sources in family study has been suggested (Pfeiffer
and others , 2008; Zheng and others , 2010; Balliu and others , 2012) in which the case-control
studies or the twin-based studies are incorporated with the family-based studies. In our
motivating example, University of Toronto Psoriatic Arthritis Registry (UTPAR) provides
data with right-truncated disease onset time and the left-truncated and right-censored
time to death (Wong and others , 1997). The UTPAR also conducts tracing studies, which
aim to yield further data on survival times for PsA patients. Another source of auxiliary
data is a national cross-sectional survey conducted by the National Psoriasis Foundation
in the United States; it yields current disease status data (Gelfand and others , 2005).
Although this study provides only marginal information, the efficiency can be enhanced
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by augmenting the likelihood. Since we have no data available on the time to disease-free
death, we use national mortality statistics to estimate the disease-free mortality rate; the
data are population-level data and so we treat λ3(·, ·) as known and define them to be the
population mortality rates. We thus consider i) registry data with follow-up ii) a cross-
sectional survey yielding current status data on disease state, and iii) national statistics
for the mortality rate.
Let A1 the set of individuals in the registry, A2 the set of individuals from the cross-
sectional survey. We multiply CLk(ψ) in (5.2.9) by the corresponding marginal likelihood
LA1 , LA2 based on auxiliary data i), ii), respectively. For the individuals in the registry
except the probands in i), we let Xr1 denote the age at onset, Cr the age at recruitment,




r , Xr2) with C
∗
r the
last assessment time, Br the calendar time of birth, and Vr a vector of covariates for an






r)|Zr(Cr) = 1, Cr, Br, Vr;φ)
where nR is a size of registry data.






P (Zr(Cr) = h|Zr(Cr) ∈ {0, 1}, Br, Vr;φ)I(Zr(Cr)=h)
where nS is the sample size of the survey. In the case of iii), we obtain λ3(t, a) using the
published population data which is calculated by the number of deaths in age-, calendar
time- divided by the exposure-to-risk in age-, calendar time- (Robert, 2017). Figures 5.3
shows the age-specific population mortality rates across calendar periods between 1921
to 2011. A decreasing trend in the age-specific mortality rates over the last 90 years is
apparent, therefore, if the registry includes individuals born over a wide range of calendar
time, age- and time-specific mortality rates should be considered.
To examine the asymptotic distribution of the estimator ψ̃, we construct the augmented
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LA2,r(φ), k = I, II, (5.2.10)


























and the maximum augmented pairwise likelihood estimator ψ̃ is obtained by solving Ū(ψ) =
0. The estimated variance of ψ̃ is given as n−1A−1(ψ̃)B(ψ̃)A−1(ψ̃)′ where








































with n = nF + nR + nS.
5.4 Simulation Studies
Here we assess the performance of the methods introduced in Section 5.2 and 5.3 through
simulation studies. To mimic more closely the PsA study, we consider the age and calendar
time-specific mortality rates based on the population mortality rates λ3(t, a) and assume
λ2(t, a) = νλ3(t, a). We set the rate of occurrence of disease λ1 = 0.01 as a constant value.
We consider the Clayton copula with Kendall’s τ = 0.2 and 0.4. We generate the time to
disease-free death from the age and time-specific population mortality rates with ν = 1.1.
We generate the family size with 4 or 6 members having two parents and 2 or 4 children
in family where P (mi + 1 = 4) = 2/3 and P (mi + 1 = 6) = 1/3. Then we randomly choose
an individual from the family members and generate the date of birth from the uniform
distribution (1920, 1950) if the individual is a parent or (1950, 1980) otherwise. Then we
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generate an individual path from the marginal distribution. We generate the individual
sampling date from the uniform distribution (1980, 2010) and select those who are alive
and diseased at the sampling date and repeat for the registry with the family sample size
nR + nF . Among nR + nF individuals who are alive at the family sampling date on July
1st of 2010, we randomly select probands and generate the data for non-probands given
the proband data with the family size nF . If the proband is a parent, the birth dates of
spouse or children are obtained by adding the uniform distribution (0, 10) or (20, 30) to
the birth date of proband, respectively, and conduct similarly when the proband is a child.
In design I, we include all non-probands data in analysis, whereas we only include alive
non-probands data in design II. In this simulation, we consider both types of auxiliary
data: the registry data with follow-up and the current status survey data. The registry
follow-up data including probands are assumed to be collected until July 1st of 2010 with
the record of death post disease. For the current status survey data, we generate the date
of birth from the uniform distribution (1930, 1980) and set the sampling date as July 1st
of 2000. We set the family sample size nF = 1000, the size of registry nR = 2000, and the
survey size nS = 1000. Here, the augmented pairwise estimations were carried out and the
results are reported in Table 5.1 for design I, and Table 5.2 for design II, respectively.
For all methods in two designs, the biases are negligible, the empirical standard errors
(ESEs) are in a good agreement with the average standard errors (ASEs), and the em-
pirical coverage probability (ECP) of nominal 95% confidence intervals are all within an
acceptable range. The estimators under the full likelihood have smaller ASEs compared
to the pairwise likelihood with the registry data; however, the current status auxiliary
data improve efficiency so that the estimators obtained by the pairwise likelihood are as
efficient as those by the full likelihood. Since the current status auxiliary data have no
time to death data, the efficiency of ν is not improved. Comparing design I and II, the
estimators have better efficiency under design I. Also, the estimators λ1 and τ under design
II are as nearly as efficient as those under design I with current status data.
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Table 5.1: Frequency properties of estimators based on the augmented pairwise likelihood
for family data given λ3(·, ·) under biased sampling scheme for the proband and disease
history of non-probands available (design I) with two auxiliary data: the registry follow-
up data and the current status survey data; Clayton copula with Kendall’s τ=0.2, 0.4;
nF = 1000, nR = 2000, nS = 1000, and nsim = 1000
Registry Data Registry + Current Status Data
τ PARAMETER EBIAS ESE ASE ECP EBIAS ESE ASE ECP
Full Likelihood
0.2 log(λ1) -0.003 0.057 0.058 0.951 -0.001 0.040 0.040 0.948
log(ν) -0.001 0.038 0.037 0.947 -0.001 0.038 0.037 0.950
τ 0.001 0.028 0.028 0.947 -0.000 0.022 0.022 0.956
0.4 log(λ1) -0.003 0.079 0.080 0.960 -0.000 0.044 0.045 0.954
log(ν) -0.002 0.037 0.036 0.952 -0.002 0.037 0.036 0.948
τ 0.002 0.033 0.033 0.950 0.001 0.021 0.021 0.953
Pairwise Likelihood
0.2 log(λ1) -0.003 0.059 0.061 0.953 -0.001 0.040 0.041 0.959
log(ν) -0.001 0.038 0.037 0.943 -0.001 0.038 0.037 0.946
τ 0.001 0.030 0.030 0.950 -0.000 0.023 0.023 0.961
0.4 log(λ1) -0.004 0.081 0.082 0.963 -0.001 0.044 0.045 0.954
log(ν) -0.002 0.037 0.036 0.951 -0.002 0.037 0.036 0.951
τ 0.002 0.035 0.034 0.957 0.001 0.022 0.021 0.962
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Table 5.2: Frequency properties of estimators based on the augmented pairwise likelihood
for family data given λ3(·, ·) under biased sampling scheme for the proband and alive non-
probands data available (design II) with two auxiliary data: the registry follow-up data
and the current status survey data; Clayton copula with Kendall’s τ=0.2, 0.4; nF = 1000,
nR = 2000, nS = 1000, and nsim = 1000
Registry Data Registry + Current Status Data
τ PARAMETER EBIAS ESE ASE ECP EBIAS ESE ASE ECP
0.2 log(λ1) -0.006 0.065 0.066 0.949 -0.001 0.042 0.042 0.948
log(ν) -0.001 0.048 0.046 0.957 -0.001 0.048 0.046 0.940
τ 0.003 0.033 0.033 0.951 0.000 0.024 0.025 0.952
0.4 log(λ1) -0.002 0.085 0.086 0.962 0.000 0.045 0.046 0.957
log(ν) -0.002 0.048 0.046 0.937 -0.002 0.046 0.047 0.938
τ 0.002 0.036 0.037 0.950 0.002 0.023 0.022 0.958
5.5 Assessment of Genetic Risk Factors
If familial aggregation is identified by the proposed model in Section 5.2 and 5.3, interest
may lie in the effect of genetic factors on disease onset to explain familial aggregation.
However, if some individuals in the study are not genotyped, incomplete genetic data must
be dealt with. For example, in design I, we may obtain the disease history for non-probands
who died but cannot sample their DNA. Also, the national current status survey data do
not provide the genetic information. Chatterjee and others (2006) proposed an analysis for
a kin-cohort case-control and case-only family data with genotype and phenotype. Gong
and others (2010) categorized two family designs: the population and the clinic designs
and present the simulation studies to examine the performance of phenotype/genotype-
based methods. Zhang and others (2010) suggested statistical methods in estimating age-
dependent penetrance under a case-family design.
In this section, we accommodate genetic data in our model but deal with missing
genetic information. We let Gij denote the genotype (gene carrier indicator), which is
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tentatively related to disease with P (Gij = 0) = q
2, P (Gij = 1) = p
2 + 2pq with the allele
frequency p and q = 1 − p for individual j in family i and Gi = (Gi0, . . . , Gimi)′. We
denote Wij = (V
′
ij, Gij)






transition intensities, then, are written as λl(t, a|bij, wij) for l = 1, 2, 3 where vij is replaced
with wij. The joint probability of disease onset also needs to replace V i with W i but the
cross-ratio or cause-specific hazard ratio under the Clayton copula remains the same as
θ. We make the following additional assumptions: i) The process is in Hardy-Weinberg
equilibrium and the Mendelian law holds, ii) Gij ⊥ Vij, iii) Z̄ij(s)|Gij ⊥ Gik ∀s for j 6= k,
iv) λ1(t, a|bij, wij) = λ1(a) exp(gijα + v′ijβ1), and v) λ2(t, a|bij, wij) = λ2(t, a|bij, vij) and
λ3(t, a|bij, wij) = λ3(t, a|bij).
5.5.1 Composite Likelihood with Incomplete Genetic Data
Here, we focus on the augmented pairwise conditional likelihood in Section 5.3. First, we
consider design II with two sources of auxiliary data: i) the family study data and the
registry data and ii) the family study data, the registry data, and current status data
from the survey. In the former case, all individuals are genotyped in the family study and
the registry since they are all examined, so we can assume that the genotypes are given
and the pairwise composite likelihood does not change the form of likelihood which has
the genotype variable as a covariate. However, the genotype data are not available in the
survey, so in the latter setting, we need to model Gij. The contribution of the proband to
the likelihood is then
Li0(φ) = P (Z̄i0(Ai0), Gi0|Zi0(Ci0) = 1, Ci0, Bi0, Vi0;φ)
=
P (Z̄i0(Ai0)|Gi0, Ci0, Bi0, Vi0;φ)P (Gi0)∑
g∈(0,1)
P (Zi0(Ci0) = 1|Ci0, Bi0, Gi0 = g, Vi0;φ)P (Gi0 = g)
, (5.2.11)
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where we select the proband based only on phenotype (disease status) at Ri0. Then the
contribution from the non-probands LIIi (ψ) is























ijl) ∈ {0, 1}2|Z̄i0(Ai0), Zi0(Ai0) = 1, Gi0,G
−
ijl = g,Aijl,Bijl,V ijl;ψ)P (G
−
ijl = g|Gi0)
where Gijl = (Gi0, Gij, Gil)
′ and P (G−ijl|Gi0) can be calculated using the allele frequency
f and family structure; see Appendix 5.B. For the auxiliary data, we let Gr denote the
genotype of individual r in A1 or A2 in Section 5.3. The likelihood terms based on the















P (Zr(Cr) = h|Zr(Cr) ∈ {0, 1}, Br, Gr = g, Vr)
× P (Gr = g|Zr(Cr) ∈ {0, 1}, Br, Vr)
}I(Zr(Cr)=h)
where
P (Gr = g|Zr(Cr), Br, Vr) =
P (Zr(Cr)|Gr = g,Br, Vr)P (Gr = g)∑
g∈{0,1}
P (Zr(Cr)|Gr = g,Br, Vr)P (Gr = g)
.
Secondly, we only observe the genotype of non-probands who are alive in design I, and
non-probands who did not survive to Ri are not genotyped. In this case


















where Goijl is a vector of observed genotype in family i for the pair of family member j and
l with the proband genotype on the first component, Gmijl is a vector of missing genotypes







We conducted further simulation studies to assess performance of the proposed model with
genetic risk factors. We considered a binary indicator Gij with the allele frequency p = 0.06
with a hazard ratio = exp(α) = 1.5; we do not consider additional covariates for simplicity
and otherwise adopt the same simulation settings as in Section 5.4.
We first generate the genotype for family members based on the family structure under
the Mendelian law and given the genotype we generate family members’ lifetime paths
based on the proposed model. The selection criteria remains the same as in Section 5.4.
The empirical properties of the estimators for the parameters based on design I and II are
reported in Table 5.3 and 5.4, respectively.
Here we can observe the same findings pointed out in Section 5.5. The current status
survey data do not affect the efficiency α and p because the genetic marker is not available
in the survey, however, they increase the efficiency of λ1 and Kendall’s τ in design I. This
highlights the value of the current status data when disease onset times are right-truncated
even for the dependence parameter. In design II, the current status data improve efficiency
of each estimator except the one for ν. It is therefore advantageous for score tests, in
particular, when interest lies in testing genetic effects on disease onset as it may increase
the power of such tests.
5.6 Application to the Psoriatic Arthritis Family Study
Psoriasis is an inflammatory skin disease occurring about 2-3% of the general population
and PsA(Psoriatic Arthrists) is an inflammatory arthritis disease affecting about 30% of
patients with psoriasis (Gladman, 1991; Langley and others , 2005; Eder and others , 2012).
Patients with PsA are at higher risk for death compared to the general population of
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Table 5.3: Frequency properties of estimators based on the augmented pairwise likelihood
for family data with genotype information given λ3(·, ·) under biased sampling scheme for
the proband and disease history of non-probands available (design I) with two auxiliary
data: the registry follow-up data and the current status survey data; Clayton copula with
Kendall’s τ=0.2, 0.4; nF = 1000, nR = 2000, nS = 1000, and nsim = 1000
Registry Data Registry + Current Status Data
τ PARAMETER EBIAS ESE ASE ECP EBIAS ESE ASE ECP
0.2 log(λ1) 0.002 0.057 0.059 0.952 -0.000 0.041 0.040 0.954
α -0.003 0.064 0.064 0.948 -0.002 0.064 0.064 0.947
log(ν) -0.001 0.037 0.037 0.956 -0.001 0.037 0.037 0.957
log(p) 0.002 0.055 0.056 0.947 0.002 0.055 0.055 0.947
τ -0.000 0.028 0.029 0.963 0.001 0.023 0.023 0.953
0.4 log(λ1) 0.002 0.076 0.078 0.950 0.000 0.045 0.044 0.952
α -0.002 0.057 0.058 0.948 -0.002 0.058 0.058 0.945
log(ν) -0.001 0.035 0.036 0.952 -0.001 0.035 0.036 0.946
log(p) 0.002 0.053 0.054 0.946 -0.003 0.053 0.053 0.947
τ -0.001 0.032 0.033 0.953 -0.000 0.022 0.022 0.949
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Table 5.4: Frequency properties of estimators based on the augmented pairwise likelihood
for family data with genotype information given λ3(·, ·) under biased sampling scheme for
the proband and alive non-probands data available (design II) with two auxiliary data: the
registry follow-up data and the current status survey data; Clayton copula with Kendall’s
τ=0.2, 0.4; nF = 1000, nR = 2000, nS = 1000, and nsim = 1000
Registry Data Registry + Current Status Data
τ PARAMETER EBIAS ESE ASE ECP EBIAS ESE ASE ECP
0.2 log(λ1) 0.001 0.061 0.064 0.951 -0.000 0.042 0.042 0.941
α -0.003 0.070 0.071 0.953 -0.003 0.065 0.065 0.949
log(ν) -0.001 0.047 0.046 0.951 -0.001 0.046 0.046 0.949
log(p) - - - - 0.002 0.055 0.055 0.949
τ 0.000 0.030 0.032 0.956 0.001 0.024 0.024 0.952
0.4 log(λ1) 0.004 0.081 0.082 0.955 0.001 0.046 0.045 0.951
α -0.001 0.063 0.062 0.949 -0.002 0.059 0.058 0.948
log(ν) -0.002 0.047 0.046 0.948 -0.002 0.046 0.046 0.950
log(p) - - - - 0.002 0.053 0.053 0.942
τ -0.001 0.035 0.035 0.949 0.001 0.023 0.023 0.941
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Ontario with a standardised mortality ratio of 1.36 (Gladman, 2008). Many studies showed
that psoriasis is a heritable disease; Pedersen and others (2008) reported an increased
concordance measure in monozygotic relative to dizygotic twins and Chandran and others
(2009) confirmed a high familial recurrence risk of PsA based on family studies as shown
in Moll and Wright (1973). To obtain a better sense of heredity, Gladman and Farewell
(1995); Pedersen and others (2008); Chandran and Raychaudhuri (2010); Eder and others
(2012) identified genes related to psoriasis and PsA and explored environmental factors
which increase the risk of PsA. We consider the Human Leucocyte Antigens (HLA)- B27,
and HLA-C06 by the findings of the genetic aetiology of psoriasis and psoriatic arthritis in
the literature.
We consider data from the Centre for Prognosis Studies in Rheumatic Disease at the
University of Toronto which recruited the Psoriatic Arthritis Toronto Cohort and among
1436 individuals from the registry, 150 were selected for family studies as probands. In
this family studies, family members were recruited to conduct a thorough examination
including genotype information, therefore, this study design belongs to the biased sampling
scheme design II. To simplify the analysis, we generate a number of 168 pseudo-families
from the original 150 families where two-generation families are considered with the non-
missing date of birth and genotype information and we use this pseudo-family data. In
the pseudo-family data, the family sizes range from 2 to 7 individuals; 56 families have
2 family members (1 proband and 1 non-proband), and 112 families have at least three
members. 193 individuals were diagnosed with PsA among a total of 532 individuals. 145
families have one member with PsA (i.e. proband), 21 families having two members with
PsA, and 2 families with three PsA patients in their family.
As a source of auxiliary data, we use the survey of US population in which Gelfand and
others (2005) reported the prevalence of psoriatic arthritis in 2001. In this survey, subjects
with 18 years of age or older were randomly selected and provided the status of psoriasis
and psoriatic arthritis; 328 have psoriatic arthritis among 15,307 respondents.
We begin with the model not using the genotype information. We fit a marginal model
for the age at PsA onset with piecewise constant hazards with a cut-point 40 to distinguish
early and late onset of PsA and assume λ2(t, a) = λ3(t, a)ν and λ3(t, a) is given as the age-
, calendar time- population mortality (Robert, 2017). In the registry data, individuals
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Table 5.5: Estimates of parameters based on the augmented pairwise likelihood; auxiliary
data include the University of Toronto Psoriatic Arthritis Registry and the survey from
Gelfand et al. (2005) without/with genotype variable under the Exponential model and
piecewise constant marginal model for age at PsA onset with a cut point 40
MARKER αmarker ν τ pmarker
- - 1.152 (0.016) 0.362 (0.083) -
B27 0.605 (0.239) 1.155 (0.080) 0.345 (0.085) 0.054 (0.012)
C06 0.117 (0.086) 1.155 (0.060) 0.362 (0.089) 0.115 (0.011)
with missing genotype are dealt with similarly in the survey data. Table 5.5 summarizes
the estimates of fitted model without genetic variable in the first column followed by two
univariate models with genotype HLA-B27, and HLA-C06 variables including the allele
frequency p for each genetic markers.
First, based on the model without genetic markers, we find that ν̂ = 1.152 indicating
that the ratio of the hazard of death post PsA to PsA-free death is 1.152, which is lower
than the reported value in Gladman (2008). As expected, PsA is not lethal while it
increases the risk of death. The estimate of dependence parameter is τ̂ = 0.362 ( 95% CI:
0.199, 0.525; p< 0.001) which indicates significant association between family members.
The cross ratio or the cause-specific cross ratio is θ̂ = 2.134 (95% CI: 1.354, 2.914; p
< 0.001), corresponding to 2.134 times higher risk of PsA with a family history of PsA.
We find that HLA-B27 has a significant effect on PsA onset (RR = 1.831; 95% CI: 0.137,
1.073; p=0.011) but HLA-C06 positive is not associated with an increased risk of PsA
(RR = 1.124; 95% CI: -0.052, 0.286; p=0.174). This findings are reported in literature
that HLA-C06 increases the risk of psorisis but PsA (Chandran, 2013). The allele frequency
of HLA-B27 is 0.054, which is compatible with the value of 0.061 from the national USA
prevalence of HLA-B27 (Reveille and others , 2012). HLA-C06 has the allele frequency
0.115 which is more prevalent that HLA-B27. After adjusted significant genetic marker
HLA-B27, Kendall’s τ̂ decreases to 0.345 (95% CI: 0.178, 0.512; p< 0.001) since HLA-B27
partially explains the residual familial aggregation.
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Figure 5.4: The cross-odds ratio for two siblings born in the same year 1930, 1940, 1950,
1960 (the right panel) and a child born in 1930, 1940, 1950, or 1960 given a parent born
in 1905, 1915, 1925, or 1935 (the left panel) based on the fitted model with no effect of a
genetic marker
Figure 5.4 shows the cross-odds ratio for a sibling given other sibling born in the same
year 1930, 1940, 1950, 1960 (the left panel) and a child born in 1930, 1940, 1950, 1960 given
a parent born in 1905, 1915, 1925, 1935, respectively. For the sibling pairs, two siblings
are governed by the same mortality rates belonging the same birth cohort. The cross-odds
ratio before 40 almost plateaus but showed a decreasing trend as they age because the
mortality rate increases. There is a drastic decrease in the cross-odds ratio as age increases
for the child-parent pairs compared to the sibling pairs. This difference arises due to the
higher mortality rates for parents; see Figure 5.3. Similar patterns of the cross-odds ratio
for different birth cohorts are observed, but the variation exists.
Figure 5.5 shows the marginal probability of death (state 2 and 3) and the cumulative
incidence function for the age of PsA defined in (5.2.5) for different birth cohorts at 1930,
1940, 1950, and 1960. We find that PsA itself is a rare disease with the low cumulative
incidence function.
127












































































































































































Figure 5.5: The marginal probability of death and the cumulative incidence of PsA by the
year of birth of 1930, 1940, 1950, or 1960 based on the fitted model with no effect of a
genetic marker
5.7 Discussion
In this Chapter we have proposed an illness-death model for family studies incorporating
within-family dependence in the age at disease onset via a copula model The illness-death
model offers a natural framework to consider survival bias and the Clayton copula models
retain simple interpretations of cross ratio/cause-specific cross ratio and marginal interpre-
tations of estimates of covariance. We explore two study designs for family studies with
biased sampling schemes and developed statistical methods for analysis. Pairwise compos-
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ite likelihood is utilized to ease the computational burden. We exploit auxiliary data to
address identifiability and estimability issues. Age- and calendar time-specific population
mortality rates adequately address the trend of mortality rates in family studies where
more than two generations are considered. We extend our model to study the effect of
genetic markers on risk of disease in which the availability of genotype data depends on
the study design. To be more flexible, if the motivating example concerns lethal diseases
such as cancer, we allow ν(a) to be an age-dependent function.
We restrict our attention to the case-only probands family studies. If the case-control
probands are available, it would be useful to compare the robustness to misspecification
of model assumption (Chatterjee and others , 2006) and compare the efficiency with the
case-only probands family studies. It is natural to extend our model to allow for different
dependence structures in families using a more flexible Gaussian copula (Zhong and Cook,
2016; Lakhal-Chaieb and others , 2018). It may also be useful to adopt age-, time-, and
sex-specific population mortality rates. As a future work we can examine the effect of
ignoring the survival biases arising from the case II design in standard methods of analysis
(Zhong and Cook, 2016). The sensitivity of inferences in both standard methods and the
proposed methods to within-family dependence in mortality can also be investigated using
large sample theory and simulation. As we have shown in the simulation studies in Section
5.3 and 5.5.2, the use of auxiliary data improves efficiency in estimating the marginal
parameters related to disease onset and the dependence parameter, so examination of
power improvement with auxiliary data would be of interest.
In our motivating example, we focus on the occurrence of psoriatic arthritis. However,
PsA occurs in 10-20% of patients with psoriasis and the genetic marker HLA-C06 mostly
contributes to develop psoriasis (Queiro and others , 2015). To distinguish the genetic risk
factors for psoriasis with those for PsA, we may introduce the state of psoriasis in our
analysis. Another extension would be to use multiple allele in our analysis. This leads to
computational burden due to the summation of all possible combination of genetic markers
for missing genotypes. We may use other sources of population studies to calculate the
allele frequency and we may exploit this value to assume that the allele frequency p is
known in our proposed model. This will reduce the number of parameters to estimate.
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Appendix 5.A. An Illustration of Composite Likelihood
Construction
Here we give an illustrative of how to construct the composite conditional likelihood,
described in Section 5.3. We omit the subscript i labelling family for simplicity and consider
no covariates. We consider a particular family consisting of two parents and two children
where
• the father died without disease at age of death x13 before the family recruitment time
R,
• the mother developed the disease at age x21 and survived to the time of family
recruitment at R,
• the first child, the proband, developed the disease at age x01 and survived to the
family recruitment time R, and
• the second child was disease-free and alive at the family recruitment time R.
The likelihood contribution (5.2.6) of the proband can written as
P (Z̄0(A0)|Z0(C0) = 1, C0, B0;φ) =
P (Z̄0(A0), B0;φ)
P (Z0(C0) = 1, C0, B0;φ)
. (5.A.1)
Then, numerator of (5.A.1) is given as




















λ2(B0 + s, s)ds
)
,
and the denominator of (5.A.1) is given as










λ3(B0 + u, u)du) exp(−
∫ C0
s
λ2(B0 + u, u)du)ds.
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In design I, we include information from all family members where we assume that
the disease history of the father is available. The contribution of non-probands given the





{P (Z̄−jl(A−jl)|Z̄0(A0), Z0(A0) = 1,Ajl,Bjl;ψ)}
1/2 (5.A.3)
which is given explicitly as
{P (X11 > x13, X13 = x13, X21 = x21, X23 > x21, X22 > A2|X01 = x01, X03 > x01, X02 > A0;ψ)
× P (X11 > x13, X13 = x13, X31 > A3, X33 > A3|X01 = x01, X03 > x01, X02 > A0;ψ)
× P (X21 = x21, X23 > x21, X22 > A2, X31 > A3, X33 > A3|X01 = x01, X03 > x01, X02 > A0;ψ)}1/2.
As an example, we show how to calculate the first term in above. Using the Clayton
copula and its invariance property in (5.2.2), we can write
P (X11 > x13, X13 = x13, X21 = x21, X23 > x21, X22 > A2|X01 = x01, X03 > x01, X02 > A0;ψ)
=









λ3(B1 + s, s)ds
)












λ2(B2 + s, s)ds
)
,
where ρ∗ = ρ/(1 + ρ), and F(u|X01 = x01;φ1, ρ) = C(F(u;φ1),F(x01;φ1); ρ)/F(x01;φ1).
In design II, we exclude information from the father since he died before the family







23)|Z̄0(A0), Z0(A0) = 1,A23,B23;ψ)
P (Z−23(A
−
23) ∈ {0, 1}2|Z̄0(A0), Z0(A0) = 1,A23,B23;ψ)
,
where the numerator is given as
P (X21 = x21, X23 > x21, X22 > A2, X31 > A3, X33 > A3|X01 = x01, X03 > x01, X02 > A0;ψ),
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and the denominator is given as
P (X21 > A2, X23 > A2, X31 > A3, X33 > A3|X01 = x01, X03 > x01, X02 > A0;ψ) (5.A.4)
+ P (X21 < A2, X23 > A2, X22 > A2, X31 > A3, X33 > A3|X01 = x01, X03 > x01, X02 > A0;ψ)
+ P (X21 > A2, X23 > A2, X31 < A3, X33 > A3, X32 > A3|X01 = x01, X03 > x01, X02 > A0;ψ)
+ P (X21 < A2, X23 > A2, X22 > A2, X31 < A3, X33 > A3, X32 > A3|X01 = x01, X03 > x01, X02 > A0;ψ).
We here show how to obtain the second and the last term in (5.A.4) since the first term
in (5.A.4) is straightforward.



































































λ2(B3 + v, v)dv
)
dsdy.
We suppose that two auxiliary data are used as introduced in Section 5.3. We consider
a particular individual in registry data who developed the disease at age xr1 and died at
age xr2. The likelihood contribution is
P (Z̄r(A
∗
r)|Zr(Cr) = 1, Cr, Br;φ) =
P (Z̄r(xr3), B0;φ)
P (Zr(Cr) = 1, Cr, Br;φ)
. (5.A.5)
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Then, numerator of (5.A.5) is given as




















λ2(Br + s, s)ds
)
,
and the denominator of (5.A.5) has the same form as (5.A.2) From the cross-sectional
survey, we consider an individual who developed the disease by the age at contact for
survey Cr. The likelihood contribution is
P (Zr(Cr) = 1|Zr(Cr) ∈ {0, 1}, Br) =
P (Zr(Cr) = 1, Br;φ)
P (Zr(Cr) = 0;φ) + P (Zr(Cr) = 1;φ)
where






































λ2(B0 + u, u)du
)
ds.
To compute a one dimensional integral we use the intergral function in R, and for two
dimensional integrals we directly code Gaussian-Quadrature a numerical integration algo-
rithm with 40 nodes.
Appendix 5.B. Calculation of P (Gijl)
Recall Gijl = (Gi0, Gij, Gil)
′ is a vector of genetic markers for the proband and members j
and l of family i; for families with two members we let Gij = (Gi0, Gij)
′. We can calculate
P (Gijl) based on the assumption that the process is in Hardy-Weinberg equilibrium and
following Mendel’s law, with a risk allele frequency p (Elandt-Johnson, 1971). Here, we
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consider two or three members per family for the pairwise likelihood in which we denote
Gp, Gc the genotype of a parent as Gp and the genotype of the child as Gs.
Joint distribution of alleles for different types of pairs of family members
G P (Gp, Gp) P (Gp, Gc) P (Gc, Gc)
1 1 (1− q2)2 p2q + p 1
4
p2(1 + p)2 + pq(2p+ 1)










0 0 q4 q3 1
4
q2(1 + q)2
Joint distribution of alleles for different types of triples of family members
G P (Gp1 , Gp2 , Gc) P (Gp, Gc1 , Gc2) P (Gc1 , Gc2 , Gc3)
1 1 1 p2(1 + 2q) 1
4
p2(1 + p)(5− 3p) + 1
2
pq(p+ pq + 1) 1
16
p2(1 + 3p)(7− 3p) + 1
4
pq(6p+ 3pq + 2)


















1 0 0 pq3 1
4





0 1 1 pq2 1
2



















0 0 0 q4 1
2
q3(1 + q) 1
16
q2(1 + 3q)2
Table 5.6: Joint probability model for genetic markers for two (top) or three (bottom)
family members according to their relationships
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Chapter 6
Remarks and Future Research
6.1 Overview
This thesis develops new statistical methods for different types of data arising from life
history processes to address heterogeneity and dependence. In Chapter 2, motivated by
the common setting in which recurrent exacerbations arise of an appreciable duration, we
propose a bivariate random effects model for an alternating two-state process. The time
scale governing onset of exacerbations is the time since the onset of the process (i.e. it is
conditionally Markov) whereas a conditionally semi-Markov intensity is used for recovery
from exacerbations. The individual-specific random effects address both heterogeneity for
each type of transition, and a copula model is used to accommodate dependence between
the two component random effects. Different combinations of marginal random effect
distributions and copula functions are considered, and the effect of misspecification of the
copula function is examined.
In Chapter 3, we consider the setting of a randomized clinical trial where the onset
and resolution of recurrent exacerbations are governed by the two-state process of Chapter
2, but where semiparametric marginal rate-based models are used for the analysis of the
recurrent onset times only. This is motivated by the fact that such data are routinely
analysed in this way in clinical trials but in such settings the recurrent event analysis means
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that misspecified models are being used. We examine the effect of using two different risk
set definitions, including or excluding individuals from the risk set during symptomatic
periods. We also study the impact of misspecification of risk sets on power in a clinical
trial since this represents the area of most common application.
The analysis of multiple types of recurrent events arising due to the same cause was
addressed in Chapter 4. A multivariate mixed-Poisson model was adopted to accommo-
date between-individual variation in the event and copula functions were used to link event
type-specific random effects to capture dependence between the different types of events.
A semiparametric estimation procedure is developed via an expectation-maximization al-
gorithm. For more than 2 types of events, inferences are described based on pairwise
composite likelihood with both simultaneous and two-stage estimation procedures.
In Chapter 5, attention was directed to modeling familial aggregation in the (possibly
latent) age of onset in framework of a marginal illness-death model. The dependence
structure for the (latent) age of disease onset between family members is modeled again via
copula functions. In family studies, biased sampling schemes are typically employed in the
recruitment of family members. An individual with disease is recruited first to the study
where the right-truncated disease onset times and the left-truncated survival times are
observed. Then, families of this individual, called the proband, are recruited. Depending
on the study design, complete retrospective data of non-probands may be available, or only
data from family members who can attend a clinic may be available. Both designs involve
biased sampling and raise identifiability and estimability issues. Auxiliary data is of use
to address this issue and improve efficiency of estimators. To study the genetic basis of
disease, we also accommodate genetic factors as covariates while missing genotypes were
addressed.
In the following sections we outline further research for each topic.
6.2 Ongoing Work in Alternating Two-state Processes
Several extensions are possible for alternating two-state processes. When the mortality
comes into play as is the case with chronic obstructive pulmonary disease in elderly indi-
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viduals for example,a death state may be added as an absorbing state to create a three
state process. The cumulative mean function should condition on survival states explic-
itly or marginalized over the possible times of death in this context. In the application
in Chapter 2, sampled individuals are required to have experienced hospitalizations and
individual data are accessible from the beginning of hospitalization over the subsequent
study period. The model of Chapter 2 can be generalized to reflect this sampling scheme
in the likelihood construction.
In the motivating example in Chapter 3, individuals in treatment and control arms
received the same treatment during symptomatic periods. Therefore, to examine the effi-
cacy of treatment, a focus is the treatment effect on the onset of exacerbation. However
it is challenging to obtain robust multiplicative rate-based treatment effect estimators on
symptom onset because the models are typically misspecified in a way that inconsistent
estimates are obtained. Utility-based model (Cook and others , 2003) or methods based on
the expected length of time in a particular state (Grand and Putter, 2016) are potential
frameworks worthy of further consideration.
6.3 Ongoing Work in Multi-type Recurrent Events
This general approach can be naturally extended to accommodate multi-type interval-
censored recurrent event data of the sort studied by Chen and others (2005) where the
exact event times are unavailable but counts of the number of events in consecutive intervals
of each type is known. The fact that this method is implemented using an expectation-
maximization algorithm means that it can also be naturally generalized to accommodate
settings where the event types are partially missing; see Chen and Cook (2009). An
alternative framework for analyzing multi-type recurrent events is via marginal methods
and estimating functions (Cai and Schaubel, 2004). While this can be appealing because it
is based on partially specified models it does not lend itself naturally to prediction. Fully
specified models, even when fitted under composite likelihood, can facilitate prediction of
future events of any type or all types, and exploits the history of the joint processes which
should yield more accurate and precise predictions of features of interest (Fredette and
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Lawless, 2007).
Another extension is to obtain a global estimate of a treatment effect on multi-type
events. Several approaches summarized in Wei and Glidden (1997) can be exploited for
global test statistics and we can develop sample size calculation for multiple events. This
was not explored here.
Recently, Claggett and others (2018) proposed a method for nonparametric inference
for multiple events based on a reverse counting process. This approach is appealing to have
a simple interpretation of a global treatment effect on individual’s disease process. This
method could be adopted to deal with recurrent events where the events occur repeatedly.
6.4 Ongoing Work in Family Studies
There are several exciting extensions for the works on family studies. A natural extension
is to consider multivariate genetic markers which may affect the age of disease onset. This
leads to computational burden due to the summation of all possible combination of genetic
markers for missing genotypes. We may use other sources of population studies to calculate
the allele frequency and we may exploit this value to assume that the allele frequency p is
known in our proposed model. This will reduce the number of parameters to estimate.
Another extension is to allow a different dependence structure in families using, for
example, the Gaussian copula function; this was done in Zhong and Cook (2016). The
degree of dependence may differ depending on which pair of individuals is being considered;
a weaker dependence is expected between parents than parent-child pairs from a genetic
point of view. However, in that case, a simple form of a cross ratio is not available.
Two-stage estimation is a plausible extension where registry data, the current status
survey data, and mortality rates are used to estimate marginal parameters, and at the
second stage a dependence parameter is estimated given the marginal parameter estimates.
This approach is natural in that the two sources of auxiliary data do not have information
with respect to the familial association.
Finally one may also examine how much power improves when testing genetic effects by
using additional current status survey data in design II. As shown in simulation studies,
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the efficiency of estimators increases with the survey data in design II even if sampled
individuals are not genotyped.
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(2001). Comparative analysis of psoriatic spondyloarthropathy between men and women.
Rheumatology International 21(2), 66–68.
Reveille, J. D., Hirsch, R., Dillon, C. F., Carroll, M. D. and Weisman,
M. H. (2012). The prevalence of HLA–B27 in the US: data from the US national health
and nutrition examination survey, 2009. Arthritis & Rheumatology 64(5), 1407–1411.
Robert, B. (2017). Mortality data for Canada. https://www.mortality.org/cgi-bin/
hmd/country.php?cntr=CAN&level=1.
151
Romanowski, B., Marina, R. B., Roberts, J. N., Valtrex HS230017 Study
Group and others . (2003). Patients’ preference of valacyclovir once-daily suppressive
therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized
study. Sexually Transmitted Diseases 30(3), 226–231.
Schaible, U. E. and Stefan, H. E. (2007). Malnutrition and infection: complex
mechanisms and global impacts. PLoS Med 4(5), e115.
Scheike, T. H., Holst, K. K. and Hjelmborg, J. B. (2014). Estimating heritability
for cause specific mortality based on twin studies. Lifetime Data Analysis 20(2), 210–
233.
Scheike, T. H. and Sun, Y. (2012). On cross-odds ratio for multivariate competing
risks data. Biostatistics 13(4), 680–694.
Scheike, T. H., Sun, Y., Zhang, M. and Jensen, T. K. (2010). A semiparametric
random effects model for multivariate competing risks data. Biometrika 97(1), 133–145.
Scheike, T. H., Zhang, M. J. and Gerds, T. A. (2008). Predicting cumulative
incidence probability by direct binomial regression. Biometrika 95(1), 205–220.
Schweder, T. (1970). Composable Markov processes. Journal of Applied Probability 7(2),
400–410.
Shih, J. H. and Albert, P. S. (2010). Modeling familial association of ages at onset
of disease in the presence of competing risk. Biometrics 66(4), 1012–1023.
Shih, J. H. and Chatterjee, N. (2002). Analysis of survival data from case–control
family studies. Biometrics 58(3), 502–509.
Shih, J. H. and Louis, T. A. (1995). Inferences on the association parameter in copula
models for bivariate survival data. Biometrics 51(4), 1384–1399.
The Diabetes Control and Complications Trial Research Group. (1986). The
Diabetes Control and Complications Trial (DCCT): design and methodologic consider-
ations for the feasibility phase. Diabetes 35(5), 530–545.
152
Varin, C. (2008). On composite marginal likelihoods. AStA Advances in Statistical
Analysis 92(1), 1–28.
Varin, C., Reid, N. and Firth, D. (2011). An overview of composite likelihood
methods. Statistica Sinica 21(1), 5–42.
Wei, L., Lin, D. Y. and Weissfeld, L. (1989). Regression analysis of multivariate in-
complete failure time data by modeling marginal distributions. Journal of the American
Statistical Association 84(408), 1065–1073.
Wei, L. J. and Glidden, D. V. (1997). An overview of statistical methods for multiple
failure time data in clinical trials. Statistics in Medicine 16(8), 833–839.
Wienke, A. (2010). Frailty Models in Survival Analysis . Boca Raton, FL: CRC Press.
Wong, K., Gladman, D. D., Husted, J., Long, J. A. and Farewell, V. T.
(1997). Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I.
Causes and risk of death. Arthritis & Rheumatology 40(10), 1868–1872.
Xu, J., Kalbfleisch, J. D. and Tai, B. (2010). Statistical analysis of illness–death
processes and semicompeting risks data. Biometrics 66(3), 716–725.
Xue, X. and Brookmeyer, R. (1996). Bivariate frailty model for the analysis of
multivariate survival time. Lifetime Data Analysis 2(3), 277–289.
Yusuf, S., Wittes, J., Probstfield, J. and Tyroler, H. A. (1991). Analysis and
interpretation of treatment effects in subgroups of patients in randomized clinical trials.
Jama 266(1), 93–98.
Zhang, H., Olschwang, S. and Yu, K. (2010). Statistical inference on the penetrances
of rare genetic mutations based on a case–family design. Biostatistics 11(3), 519–532.
Zhao, Y. and Joe, H. (2005). Composite likelihood estimation in multivariate data
analysis. Canadian Journal of Statistics 33(3), 335–356.
153
Zheng, Y., Heagerty, P. J., Hsu, L. and Newcomb, P. A. (2010). On combining
family-based and population-based case–control data in association studies. Biomet-
rics 66(4), 1024–1033.
Zhong, Y. and Cook, R. J. (2016). Augmented composite likelihood for copula mod-
eling in family studies under biased sampling. Biostatistics 17(3), 437–452.
Zhong, Y. and Cook, R. J. (2017). Second-order estimating equations for clustered
current status data from family studies using response-dependent sampling. Statistics
in Biosciences 10(1), 1–24.
Zhou, B., Fine, J., Latouche, A. and Labopin, M. (2012). Competing risks regres-
sion for clustered data. Biostatistics 13(3), 371–383.
154
